Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors

ABSTRACT

This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.

REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Ser. No. 08/945,840, filed Sep.14, 1998, which is a 371 of PCT/US96/08314, filed May 31, 1996, which isa continuation of Ser. No. 08/458,545, filed Jun. 2, 1995, nowabandoned.

FIELD OF THE INVENTION

This invention is in the field of antiinflammatory pharmaceutical agentsand specifically relates to compounds, compositions and methods fortreating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, suchas inflammation and allergic conditions such as asthma.

BACKGROUND OF THE INVENTION

Prostaglandins play a major role in the inflammation process, and theinhibition of prostaglandin production, especially production of PGG₂,PGH₂ and PGE₂, has been a common target of antiinflammatory drugdiscovery. However, common non-steroidal antiinflammatory drugs (NSAIDs)that are active in reducing the prostaglandin-induced pain and swellingassociated with the inflammation process are also active in affectingother prostaglandin-regulated processes not associated with theinflammation process. Thus, use of high doses of most common NSAIDs canproduce severe side effects, including life threatening ulcers, thatlimit their therapeutic potential. An alternative to NSAIDs is the useof corticosteroids, which have even more drastic side effects,especially when long term therapy is involved.

Previous NSAIDs have been found to prevent the production ofprostaglandins by inhibiting enzymes in the human arachidonicacid/prostaglandin pathway including the enzyme cyclooxygenase (COX).The recent discovery of an inducible enzyme associated with inflammation(named “cyclooxygenase-2 (COX-2)” or “prostaglandin G/H synthase II”)provides a viable target of inhibition which more effectively reducesinflammation and produces fewer and less drastic side effects.

In another portion of the arachidonic acid pathway, physiologicallyactive leukotrienes, such as leukotriene B₄ (LTB₄), leukotriene C₄(LTC₄) and leukotriene D₄ (LTD₄) and other metabolites, are produced bythe 5-lipoxygenase-mediated (5-LO) oxidation of arachidonic acid. Theseleukotrienes have been implicated in various inflammation-relateddisorders and allergic diseases, and thus compounds which inhibit5-lipoxygenase are useful in the treatment of disease states in whichleukotrienes play an important role.

It is believed that selective dual inhibitors of both cyclooxygenase-2and 5-lipoxygenase, which affect the two enzymes at low concentrations,will more completely and permanently affect the damage caused by thevarious diseases and disorders mediated by cyclooxygenase-2 and5-lipoxygenase but without the gastrointestinal side effects associatedwith traditional NSAIDs.

The references below that disclose antiinflammatory activity, showcontinuing efforts to find a safe and effective antiinflammatory agent.The novel compounds disclosed herein are such safe and also effectiveantiinflammatory agents furthering such efforts. The compounds disclosedherein preferably selectively inhibit cyclooxygenase-2 overcyclooxygenase-1.

Compounds which selectively inhibit cyclooxygenase-2 have been describedin U.S. Pat. Nos. 5,380,738, 5,344,991, 5,393,790 and WO documentsWO94/15932, WO94/27980, WO95/00501, WO94/13635, WO94/20480, andWO94/26731.

Compounds which inhibit 5-lipoxygenase have been described in U.S. Pat.Nos. 5,364,877, 5,302,603, 5,234,950, 5,098,932 and 5,354,865, amongothers.

Compounds which inhibit both cyclooxygenase and 5-lipoxygenase have beendescribed in U.S. Pat. Nos. 5,051,518, 5,298,521, 5,242,940, 5,234,939,and 5,356,898, among others. However, these previous mixed inhibitors donot selectively inhibit cyclooxygenase-2 and therefore still cause thegastrointestinal side effects which substantially reduce their usage andeffectiveness.

The invention's compounds are found to show usefulness as dualinhibitors of cyclooxygenase-2 and 5-lipoxygenase with minimal sideeffects.

DESCRIPTION OF THE INVENTION

A class of compounds useful in treating cyclooxygenase-2 and5-lipoxygenase-mediated disorders is defined by Formula I:

wherein A is a 5- or 6-member ring substituent selected from partiallyunsaturated or unsaturated heterocyclo and carbocyclic rings, wherein Ais optionally substituted with a radical selected from acyl, halo,alkyl, haloalkyl, cyano, nitro, carboxyl, alkoxy, oxo, aminocarbonyl,alkoxycarbonyl, carboxyalkyl, cyanoalkyl, and hydroxyalkyl;

wherein Y is one or more radicals selected from alkyl, alkynyl, alkenyl,hydroxyalkyl, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, acyl, aryl,aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclo and heterocycloalkyl;

wherein R¹ is one or more substituents selected from heterocyclo,cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substitutedat a substitutable position with one or more radicals selected fromalkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl,hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro,alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

wherein R² is selected from alkyl and amino;

wherein R³ is a direct bond or a radical selected from

wherein R⁴ is selected from hydrido, hydroxyl, alkyl, aryl, heterocycloand cycloalkyl;

wherein R⁵ is selected from hydrido, alkyl, aryl, heterocyclo andcycloalkyl; and

wherein R⁶ is selected from hydrido and hydroxyl; provided R² is aminowhen A is pyrazolyl;

or a pharmaceutically-acceptable salt thereof.

Compounds of Formula I would be useful for, but not limited to, thetreatment of inflammation in a subject, and for treatment of otherinflammation-associated disorders, such as, as an analgesic in thetreatment of pain and headaches, or as an antipyretic for the treatmentof fever. For example, compounds of the invention would be useful totreat arthritis, including but not limited to rheumatoid arthritis,spondyloarthopathies, gouty arthritis, osteoarthritis, systemic lupuserythematosus and juvenile arthritis. Such compounds of the inventionwould be useful in the treatment of asthma, bronchitis, menstrualcramps, tendinitis, bursitis, skin-related conditions such as psoriasis,eczema, burns and dermatitis, and from post-operative inflammationincluding from ophthalmic surgery such as cataract surgery andrefractive surgery. Compounds of the invention also would be useful totreat gastrointestinal conditions such as inflammatory bowel disease,Crohn's disease, gastritis, irritable bowel syndrome andulcerative-colitis, and for the prevention or treatment of cancer, suchas colorectal cancer. Compounds of the invention would be useful intreating inflammation in such diseases as vascular diseases, migraineheadaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin'sdisease, sclerodoma, rheumatic fever, type I diabetes, neuromuscularjunction disease including myasthenia gravis, white matter diseaseincluding multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet'ssyndrome, polymyositis, gingivitis, nephritis, hypersensitivity,swelling occurring after injury, myocardial ischemia, and the like. Thecompounds would also be useful in the treatment of ophthalmic diseases,such as retinitis, retinopathies, uveitis, ocular photophobia, and ofacute injury to the eye tissue. The compounds would also be useful inthe treatment of pulmonary inflammation, such as that associated withviral infections and cystic fibrosis. The compounds would also be usefulfor the treatment of certain central nervous system disorders such ascortical dementias including Alzheimer's disease. The compounds of theinvention are useful as anti-inflammatory agents, such as for thetreatment of arthritis, with the additional benefit of havingsignificantly less harmful side effects. These compounds would also beuseful in the treatment of allergic rhinitis, respiratory distresssyndrome, endotoxin shock syndrome, atherosclerosis and central nervoussystem damage resulting from stroke, ischemia and trauma. The compoundswould also be useful in the treatment of pain, but not limited topostoperative pain, dental pain, muscular pain, and pain resulting fromcancer.

Besides being useful for human treatment, these compounds are alsouseful for treatment of mammals, including horses, dogs, cats, rats,mice, sheep, pigs, etc.

The present compounds may also be used in co-therapies, partially orcompletely, in place of other conventional antiinflammatories, such astogether with steroids, NSAIDs, LTB4 antagonists and LTA₄ hydrolaseinhibitors.

Suitable LTB₄ inhibitors include, among others, ebselen, BayerBay-x-1005, Ciba Geigy compound CGS-25019C, Leo Denmark compoundETH-615, Lilly compound LY-293111, Ono compound ONO-4057, Terumocompound TMK-688, Lilly compounds LY-213024, 264086 and 292728, Onocompound ONO-LB457, Searle compound SC-53228, calcitrol, Lilly compoundsLY-210073, LY223982, LY233469, and LY255283, ONO compound ONO-LB-448,Searle compounds SC-41930, SC-50605 and SC-51146, and SK&F compoundSKF-104493. Preferably, the LTB₄ inhibitors are selected from ebselen,Bayer Bay-x-1005, Ciba Geigy compound CGS-25019C, Leo Denmark compoundETH-615, Lilly compound LY-293111, Ono compound ONO-4057, and Terumocompound TMK-688.

Suitable 5-LO inhibitors include, among others, masoprocol, tenidap,zileuton, pranlukast, tepoxalin, rilopirox, flezelastine hydrochloride,enazadrem phosphate, and bunaprolast.

The present invention preferably includes compounds which selectivelyinhibit cyclooxygenase-2 over cyclooxygenase-1 as well as inhibit the5-lipoxygenase enzyme. Preferably, the compounds have a cyclooxygenase-2IC₅₀ of less than about 10 μM, and also have a selectivity ratio ofcyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least10, and more preferably of at least 100, and inhibit 5-lipoxygenase atless than about 10 μM. Even more preferably, the compounds have acyclooxygenase-1 IC₅₀ of greater than about 10 μM, and more preferablyof greater than 20 μM and have a 5-lipoxygenase IC₅₀ of less than about1 μM. Such preferred selectivity may indicate an ability to reduce theincidence of common NSAID-induced side effects.

A preferred class of compounds consists of those compounds of Formula Iwherein A is selected from thienyl, oxazolyl, furyl, pyrrolyl,thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl,cyclopentenyl, phenyl, and pyridyl, wherein A is optionally substitutedwith a radical selected from acyl, halo, lower alkyl, lower haloalkyl,oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, loweralkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lowerhydroxyalkyl; wherein Y is a radical selected from lower alkyl, loweralkynyl, lower alkenyl, lower hydroxyalkyl, lower aminoalkyl, loweralkylaminoalkyl, lower arylaminoalkyl, lower acyl, aryl, lower aralkyl,lower cycloalkyl, lower cycloalkylalkyl, 5- or 6-membered heterocycloand lower heterocycloalkyl; wherein R¹ is one or more substituentsselected from 5- and 6-membered heterocyclo, lower cycloalkyl, lowercycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, whereR¹ is optionally substituted at a substitutable position with one ormore radicals selected from lower alkyl, lower haloalkyl, cyano,carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lowerhaloalkoxy, amino, lower alkylamino, phenylamino, nitro, loweralkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and loweralkylthio; wherein R² is selected from lower alkyl and amino; wherein R³is a direct bond or a radical selected from

wherein R⁴ is selected from hydrido, hydroxyl, lower alkyl, phenyl, 5-and 6-membered heterocyclo and lower cycloalkyl; wherein R⁵ is selectedfrom hydrido, lower alkyl, phenyl, 5- and 6-membered heterocyclo andlower cycloalkyl; and wherein R⁶ is selected from hydrido and hydroxyl;or a pharmaceutically-acceptable salt thereof.

A class of compounds of particular interest consists of those compoundsof Formula I wherein A is a radical selected from thienyl, oxazolyl,furyl, pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl,cyclopentenyl, phenyl, and pyridyl, wherein A is optionally substitutedwith a radical selected from formyl, fluoro, chloro, bromo, methyl,trifluoromethyl, oxo, cyano, carboxyl, methoxy, aminocarbonyl,methoxycarbonyl, ethoxycarbonyl, acetyl, carboxypropyl, andhydroxymethyl; wherein Y is a radical selected from ethyl, propyl,isopropyl, butyl, 1-propynyl, 2-propynyl, 1-butyn-3-yl, 1-propenyl,2-propenyl, acetyl, dihydroxypropyl, hydroxyethyl, 1-amino-ethyl,1-amino-propyl, 1-(N-methylamino)propyl, 1-(N,N-dimethylamino)propyl,1-(N-phenylamino)propyl, triazolyl, thienyl, benzyl, phenylethyl,cyclohexylmethyl, cyclopentylethyl, triazolylmethyl, thienylmethyl andphenyl optionally substituted at a substitutable position with one ormore radicals selected from fluoro, chloro, bromo, hydroxyl, methyl, andmethoxy; wherein R¹ is a substituent selected from thienyl, oxazolyl,furyl, pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl, pyridyl,and phenyl, where R¹ is optionally substituted at a substitutableposition with one or more radicals selected from methyl,trifluoromethyl, hydroxyl, hydroxymethyl, trifluoromethoxy, nitro,methoxymethyl, fluoro, chloro, bromo, methoxy and methylthio; wherein R²is methyl or amino; wherein R³ is a direct bond or a radical selectedfrom

wherein R⁴ is selected from hydrido, hydroxyl, methyl, and phenyl;wherein R⁵ is selected from hydrido, methyl, and phenyl; and wherein R⁶is selected from hydrido and hydroxyl; or a pharmaceutically-acceptablesalt thereof.

Within Formula I there is a subclass of compounds of high interestrepresented by Formula II:

wherein A is a ring substituent selected from thienyl, oxazolyl, furyl,pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl,cyclopentenyl, phenyl, and pyridyl; wherein A is optionally substitutedwith a radical selected from acyl, halo, hydroxyl, lower alkyl, lowerhaloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl,lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lowerhydroxyalkyl; wherein Y is selected from lower alkyl, lower alkenyl andlower alkynyl; wherein R¹ is selected from 5- and 6-memberedheterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected fromphenyl, biphenyl and naphthyl, wherein R¹ is optionally substituted at asubstitutable position with one or more radicals selected from loweralkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl,lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino,phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, loweralkoxy and lower alkylthio; wherein R² is selected from lower alkyl andamino; and wherein R⁵ is selected from hydrido, lower alkyl, phenyl, 5-and 6-membered heterocyclo and lower cycloalkyl; provided R² is aminowhen A is pyrazolyl; or a pharmaceutically-acceptable salt thereof.

A class of compounds of particular interest consists of those compoundsof Formula II wherein A is selected from thienyl, oxazolyl, furyl,pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl, cyclopentenyl,phenyl, and pyridyl, wherein A is optionally substituted with a radicalselected from formyl, fluoro, chloro, bromo, methyl, trifluoromethyl,oxo, cyano, carboxyl, methoxy, aminocarbonyl, methoxycarbonyl,ethoxycarbonyl, acetyl, carboxypropyl, and hydroxymethyl; wherein Y is aradical selected from methyl, ethyl, isopropyl, propyl, butyl, propenyl,butenyl, propynyl and butynyl; wherein R¹ is selected from thienyl,oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl,pyridyl, and phenyl, where R¹ is optionally substituted at asubstitutable position with one or more radicals selected from methyl,trifluoromethyl, hydroxyl, hydroxymethyl, trifluoromethoxy,methoxymethyl, fluoro, chloro, bromo, methoxy and methylthio; wherein R²is methyl or amino; and wherein R⁵ is selected from hydrido, methyl, andphenyl; or a pharmaceutically-acceptable salt thereof.

Within Formula I there is a second subclass of compounds of highinterest represented by Formula III:

wherein A is a ring substituent selected from thienyl, oxazolyl, furyl,pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl,cyclopentenyl, phenyl, and pyridyl; wherein A is optionally substitutedwith a radical selected from acyl, halo, hydroxyl, lower alkyl, lowerhaloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl,lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lowerhydroxyalkyl; wherein Y is selected from lower alkyl, lower alkenyl andlower alkynyl; wherein R¹ is selected from 5- and 6-memberedheterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected fromphenyl, biphenyl and naphthyl, wherein R¹ is optionally substituted at asubstitutable position with one or more radicals selected from loweralkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl,lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino,phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, loweralkoxy and lower alkylthio; wherein R² is selected from lower alkyl andamino; and wherein R⁵ is selected from hydrido and alkyl; or apharmaceutically-acceptable salt thereof.

A class of compounds of particular interest consists of those compoundsof Formula III wherein A is selected from thienyl, oxazolyl, furyl,pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl, cyclopentenyl,phenyl, and pyridyl, wherein A is optionally substituted with a radicalselected from formyl, fluoro, chloro, bromo, methyl, trifluoromethyl,oxo, cyano, carboxyl, methoxy, aminocarbonyl, methoxycarbonyl,ethoxycarbonyl, acetyl, carboxypropyl, and hydroxymethyl; wherein Y isselected from methyl, ethyl, isopropyl, propyl, butyl, propenyl,butenyl, propynyl and butynyl; wherein R¹ is selected from thienyl,oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl,pyridyl, and phenyl, where R¹ is optionally substituted at asubstitutable position with one or more radicals selected from methyl,trifluoromethyl, hydroxyl, hydroxymethyl, trifluoromethoxy,methoxymethyl, fluoro, chloro, bromo, methoxy and methylthio; wherein R²is methyl or amino; and wherein R⁵ is selected from hydrido, and methyl;or a pharmaceutically-acceptable salt thereof.

A class of compounds of particular interest consists of those compoundsof Formula I

[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]methyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-phenyl-5-isoxazolyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-5-isoxazolyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-5-isoxazolyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-5-isoxazolyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-5-isoxazolyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-5-isoxazolyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-5-isoxazolyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-methylsulfonyl)phenyl]-3-phenyl-5-isoxazolyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[3-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-5-isoxazolyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-phenyl-2-thienyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-2-thienyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-2-thienyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-2-thienyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-2-thienyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-2-thienyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-2-thienyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[3-[(4-methylsulfonyl)phenyl]-4-phenyl-5-thienyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-5-thienyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-6-phenyl-3-pyridyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-6-(4-chlorophenyl)-3-pyridyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-6-(4-fluorophenyl)-3-pyridyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-6-(4-methoxyphenyl)-3-pyridyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[6-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-3-pyridyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[6-[(4-aminosuiLonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-3-pyridyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-6-(3-chloro-4-fluorophenyl)-3-pyridyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-methylsulfonyl)phenyl]-6-phenyl-3-pyridyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-(4-chlorophenyl)-6-[(4-methylsulfonyl)phenyl]-3-pyridyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-phenyl-2-furyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-2-furyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-2-furyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-furyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-2-furyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-furyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-2-furyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-methylsulfonyl)phenyl]-3-phenyl-2-furyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-furyl]propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-1-propyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

1-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-(4-chiorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-propenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithidcarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

[3-[1-(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-1-methyl-2-propynyl-N-hydroxy-N-methyl-dithiocarbamate;

[[4-[(4-aminosulfonyl)phenyl]-3-phenyl-5-isoxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-5-isoxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-5-isoxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-5-isoxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-5-isoxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-5-isoxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-5-isoxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-methylsulfonyl)phenyl]-3-phenyl-5-isoxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[3-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-5-isoxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-phenyl-2-thienyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-2-thienyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-2-thienyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-2-thienyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-2-thienyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-2-thienyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-2-thienyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[3-[(4-methylsulfonyl)phenyl]-4-phenyl-5-thienyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-5-thienyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-6-phenyl-3-pyridyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-6-(4-chlorophenyl)-3-pyridyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-6-(4-fluorophenyl)-3-pyridyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-6-(4-methoxyphenyl)-3-pyridyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[6-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-3-pyridyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[6-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-3-pyridyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-6-(3-chloro-4-fluorophenyl)-3-pyridyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-methylsulfonyl)phenyl]-6-phenyl-3-pyridyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-(4-chlorophenyl)-6-[(4-methylsulfonyl)phenyl]-3-pyridyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-phenyl-2-furyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-2-furyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-2-furyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-furyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-2-furyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-furyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-2-furyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-methylsulfonyl)phenyl]-3-phenyl-2-furyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-furyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-1-methyl-2-propenyl]-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]phenyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[4-[(4-methylsulfonyl)phenyl]-5-cyclohexyl-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[5-[(4-methylsulfonyl)phenyl]-4-cyclohexenyl-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

5-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]1,2,3-triazol-4-ylmethyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[4-[(4-methylsulfonyl)phenyl]-5-cyclohexyl-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[5-[(4-methylsulfonyl)phenyl]-4-cyclohexenyl-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

3-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]cyclohexyl-N-hydroxy-N-methyl-dithiocarbamate;

4-[(4-aminosulfonyl)phenyl]-5-(3,4-dichlorophenyl)-N-hydroxy-2-oxazolebutanamide;

4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-5-phenyl-2-oxazolebutanamide;

4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-N-hydroxy-2-oxazolebutanamide;

5-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-2-oxazolebutanamide;

5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-N-hydroxy-2-oxazolebutanamide;

5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-N-hydroxy-N-methyl-2-oxazolebutanamide;

5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-N-hydroxy-2-oxazolebutanamide;

5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-N-hydroxy-2-oxazolebutanamide;

5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazolebutanamide;

5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-N-hydroxy-2-oxazolebutanamide;

N-hydroxy-N-methyl-4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolebutanamide;

5-(4-chlorophenyl)-N-hydroxy-N-methyl-4-[(4-methylsulfonyl)phenyl]-2-oxazolebutanamide;

5-[(4-methylsuifonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-2-oxazolebutanamide;

4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-N-hydroxy-2-oxazolebutanamide;

1-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-5-phenyl-3-pyrazolebutanamide;

1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-N-hydroxy-N-methyl-3-pyrazolebutanamide;

1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-N-hydroxy-N-methyl-3-pyrazolebutanamide;

1-[(4-aminosulfonyl)phenyl]-5-(4-methylphenyl)-N-hydroxy-N-methyl-3-pyrazolebutanamide;

1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methylphenyl)-N-hydroxy-3-pyrazolebutanamide;

1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methylphenyl)-N-hydroxy-3-pyrazolebutanamide;

1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-N-hydroxy-3-pyrazolebutanamide;

4-[(4-aminosulfonyl)phenyl]-N-hydroxy-3-phenyl-5-isoxazole-N-methyl-butanamide;

4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-N-hydroxy-5-isoxazole-N-methyl-butanamide;

4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-N-hydroxy-5-isoxazole-N-methyl-butanamide;

4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-N-hydroxy-5-isoxazole-butanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-N-hydroxy-5-isoxazole-butanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-N-hydroxy-5-isoxazole-butanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-N-hydroxy-5-isoxazole-butanamide;

4-[(4-methylsulfonyl)phenyl]-N-hydroxy-3-phenyl-5-isoxazole-N-methyl-butanamide;

3-(4-chlorophenyl)-N-hydroxy-N-methyl-4-[(4-methylsulfonyl)phenyl]-5-isoxazolebutanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3,4-dichlorophenyl)-N-hydroxy-5-isoxazole-N-methyl-butanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3-fluorophenyl)-N-hydroxy-5-isoxazole-N-methyl-butanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3-fluorophenyl)-N-hydroxy-5-isoxazole-butanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3,4-dichlorophenyl)-N-hydroxy-5-isoxazole-butanamide;

3-(3-fluorophenyl)-4-[(4-methylsulfonyl)phenyl]-N-hydroxy-5-isoxazole-N-methyl-butanamide;

3-(3,4-dichlorophenyl)-N-hydroxy-4-[(4-methylsulfonyl)phenyl]-5-isoxazolebutanamide;

4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-3-phenyl-2-thiophenebutanamide;

4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-N-hydroxy-N-methyl-2-thiophenebutanamide;

4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-N-hydroxy-N-methyl-2-thiophenebutanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-N-hydroxy-N-methyl-2-thiophenebutanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-N-hydroxy-2-thiophenebutanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-N-hydroxy-2-thiophenebutanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-N-hydroxy-2-thiophenebutanamide;

[3-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-5-thiophenebutanamide;

[4-(4-chlorophenyl)-N-hydroxy-N-methyl-3-[(4-methylsulfonyl)phenyl]-5-thiophenebutanamide;

[5-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-6-phenyl-3-pyridinebutanamide;

[5-[(4-aminosulfonyl)phenyl]-6-(4-chlorophenyl)-N-hydroxy-3-pyridinebutanamide;

[5-[(4-aminosulfonyl)phenyl]-6-(4-fluorophenyl)-N-hydroxy-N-methyl-3-pyridinebutanamide;

[5-[(4-aminosulfonyl)phenyl]-6-(4-methoxyphenyl)-N-hydroxy-N-methyl-3-pyridinebutanamide;

[6-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-N-hydroxy-3-pyridinebutanamide;

[6-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-3-fluoro-4-methoxyphenyl)-N-hydroxy-3-pyridinebutanamide;

[5-[(4-aminosulfonyl)phenyl]-6-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-3-pyridinebutanamide;

[5-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-6-phenyl-3-pyridinebutanamide;

[5-(4-chlorophenyl)-N-hydroxy-6-[(4-methylsulfonyl)phenyl]-3-pyridinebutanamide;

[4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-3-phenyl-2-furanbutanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-N-hydroxy-2-furanbutanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-N-hydroxy-N-methyl-2-furanbutanamide;

[5-[(4-aminosulfonyl)phenyl]-N-hydroxy-4-(4-methoxyphenyl)-2-furanbutanamide;

[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-N-hydroxy-2-furanbutanamide;

[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-N-hydroxy-2-furanbutanamide;

[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-2-furanbutanamide;

[4-[(4-methylsulfonyl)phenyl]-N-hydroxy-3-phenyl-2-furanbutanamide;

[4-(4-chlorophenyl)-N-hydroxy-N-methyl-5-[(4-methylsulfonyl)phenyl]-2-furanbutanamide;

4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-5-phenyl-2-oxazolepropanamide;

4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-N-hydroxy-N-methyl-2-oxazolepropanamide;

5-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-2-oxazolepropanamide;

5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-N-hydroxy-N-methyl-2-oxazolepropanamide;

5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-N-hydroxy-N-methyl-2-oxazolepropanamide;

5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazolepropanamide;

5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazolepropanamide;

5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazolepropanamide;

5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-2-oxazolepropanamide;

N-hydroxy-N-methyl-4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolepropanamide;

5-(4-chlorophenyl)-N-hydroxy-N-methyl-4-[(4-methylsulfonyl)phenyl]-2-oxazolepropanamide;

5-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-2-oxazolepropanamide;

4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-2-oxazolepropanamide;

1-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-5-phenyl-3-pyrazolepropanamide;

1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-N-hydroxy-N-methyl-3-pyrazolepropanamide;

1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-N-hydroxy-N-methyl-3-pyrazolepropanamide;

1-[(4-aminosulfonyl)phenyl]-5-(4-methylphenyl)-N-hydroxy-N-methyl-3-pyrazolepropanamide;

1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methylphenyl)-N-hydroxy-N-methyl-3-pyrazolepropanamide;

1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methylphenyl)-N-hydroxy-N-methyl-3-pyrazolepropanamide;

1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-3-pyrazolepropanamide;

4-[(4-aminosulfonyl)phenyl]-N-hydroxy-3-phenyl-5-isoxazole-N-methyl-propanamide;

4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-N-hydroxy-5-isoxazole-N-methyl-propanamide;

4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-N-hydroxy-5-isoxazole-N-methyl-propanamide;

4-(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-N-hydroxy-5-isoxazole-N-methyl-propanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-N-hydroxy-5-isoxazole-N-methyl-propanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-N-hydroxy-5-isoxazole-N-methyl-propanamide;

4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-N-hydroxy-5-isoxazole-N-methyl-propanamide;

4-[(4-methylsulfonyl)phenyl]-N-hydroxy-3-phenyl-5-isoxazole-N-methyl-propanamide;

3-(4-chlorophenyl)-N-hydroxy-N-methyl-4-(4-methylsulfonyl)phenyl]-5-isoxazolepropanamide;

4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-3-phenyl-2-thiophenepropanamide;

4-(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-N-hydroxy-N-methyl-2-thiophenepropanamide;

4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-N-hydroxy-N-methyl-2-thiophenepropanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-N-hydroxy-N-methyl-2-thiophenepropanamide;

[4-[(4-aminosulronyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-thiophenepropanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-thiophenepropanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-2-thiophenepropanamide;

[3-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-5-thiophenepropanamide;

[4-(4-chlorophenyl)-N-hydroxy-N-methyl-3-[(4-methylsulfonyl)phenyl]-5-thiophenepropanamide;

[5-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-6-phenyl-3-pyridinepropanamide;

[5-[(4-aminosulfonyl)phenyl]-6-(4-chlorophenyl)-N-hydroxy-N-methyl-3-pyridinepropanamide;[5-[(4-aminosulfonyl)phenyl]6-(4-fluorophenyl)-N-hydroxy-N-methyl-3-pyridinepropanamide;

[5-[(4-aminosulfonyl)phenyl]-6-(4-methoxyphenyl)-N-hydroxy-N-methyl-3-pyridinepropanamide;

[6-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-N-hydroxy-N-methyl-3-pyridinepropanamide;

[6-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-3-pyridinepropanamide;

[5-[(4-aminosulfonyl)phenyl]-6-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-3-pyridinepropanamide;

[5-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-6-phenyl-3-pyridinepropanamide;

[5-(4-chlorophenyl)-N-hydroxy-N-methyl-6-[(4-methylsulfonyl)phenyl]-3-pyridinepropanamide;

[4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-3-phenyl-2-furanpropanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-N-hydroxy-N-methyl-2-furanpropanamide;

[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-N-hydroxy-N-methyl-2-furanpropanamide;

[5-[(4-aminosulfonyl)phenyl]-N-hydroxy-4-(4-methoxyphenyl)-N-methyl-2-furanpropanamide;

[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-furanpropanamide;

[5-(4-aminosulfonyl) phenyl4-(3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-furanpropanamide;

[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-2-furanpropanamide;

[4-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-3-phenyl-2-furanpropanamide;

[4-(4-chlorophenyl)-N-hydroxy-N-methyl-5-[(4-methylsulfonyl)phenyl]-2-furanpropanamide;

4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-5-phenyl-2-oxazole-ethanamide;

4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-N-hydroxy-N-methyl-2-oxazole-ethanamide;

5-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-2-oxazole-ethanamide;

5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-N-hydroxy-N-methyl-2-oxazole-ethanamide;

5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-N-hydroxy-N-methyl-2-oxazole-ethanamide;

5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazole-ethanamide;

5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazole-ethanamide;

5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazole-ethanamide;

5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-2-oxazole-ethanamide;

4-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-5-phenyl-2-oxazole-ethanamide;

5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-2-oxazole-ethanamide;

5-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-2-oxazole-ethanamide;

4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-2-oxazole-ethanamide;

[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-ethanamide;

1-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-2-propenamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-propenamide;

1-3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-propenamide;

1-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-(4-chlorophenyl)-4-(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-2-propynamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-propynamide;

1-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-5-phenyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-N-hydroxy-N-methyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[5-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-N-hydroxy-N-methyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-N-hydroxy-N-methyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[N-hydroxy-N-methyl-4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[5-(4-chlorophenyl)-N-hydroxy-N-methyl-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-2-propynamide;

2-methyl-3-[5-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[4-[4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-2-oxazolyl]-2-propynamide;

2-methyl-3-[1-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-5-phenyl-1H-pyrazol-3-yl]-2-propynamide;

2-methyl-3-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-N-hydroxy-N-methyl-1H-pyrazol-3-yl]-2-propynamide;

2-methyl-3-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-N-hydroxy-N-methyl-1H-pyrazol-3-yl]-2-propynamide;

2-methyl-3-[1-[(4-aminosulfonyl)phenyl]-5-(4-methylphenyl)-N-hydroxy-N-methyl-1H-pyrazol-3-yl]-2-propynamide;

2-methyl-3-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methylphenyl)-N-hydroxy-N-methyl-1H-pyrazol-3-yl]-2-propynamide;

2-methyl-3-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methylphenyl)-N-hydroxy-N-methyl-1H-pyrazol-3-yl]-2-propynamide;

2-methyl-3-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-1H-pyrazol-3-yl]-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-N-hydroxy-3-phenyl-5-isoxazolyl]-N-methyl-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-N-hydroxy-5-isoxazolyl]-N-methyl-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-N-hydroxy-5-isoxazolyl]-N-methyl-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-N-hydroxy-5-isoxazolyl]-N-methyl-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-N-hydroxy-5-isoxazolyl]-N-methyl-2-propynamide;

2-methyl-3-4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-N-hydroxy-5-isoxazolyl]-N-methyl-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-N-hydroxy-5-isoxazolyl]-N-methyl-2-propynamide;

2-methyl-3-[4-[(4-methylsulfonyl)phenyl]-N-hydroxy-3-phenyl-5-isoxazolyl]-N-methyl-2-propynamide;

2-methyl-3-[3-(4-chlorophenyl)-N-hydroxy-N-methyl-4-[(4-methylsulfonyl)phenyl]-5-isoxazolyl]-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-3-phenyl-2-thienyl]-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-N-hydroxy-N-methyl-2-thienyl]-2-propynamide;

2-methyl-3-[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-N-hydroxy-N-methyl-2-thienyl]-2-propynamide;

2-methyl-3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-N-hydroxy-N-methyl-2-thienyl]-2-propynamide;

2-methyl-3-[[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-thienyl]-2-propynamide;

2-methyl-3-[[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-thienyl]-2-propynamide;

2-methyl-3-[[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-2-thienyl]-2-propynamide;

2-methyl-3-[[3-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-4-phenyl-5-thienyl]-2-propynamide;

2-methyl-3-[[4-(4-chlorophenyl)-N-hydroxy-N-methyl-3-[(4-methylsulfonyl)phenyl]-5-thienyl]-2-propynamide;

2-methyl-3-[[5-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-6-phenyl-3-pyridyl]-2-propynamide;

2-methyl-3-[[5-[(4-aminosulfonyl)phenyl]-6-(4-chlorophenyl)-N-hydroxy-N-methyl-3-pyridyl]-2-propynamide;

2-methyl-3-[[5-[(4-aminosulfonyl)phenyl]-6-(4-fluorophenyl)-N-hydroxy-N-methyl-3-pyridyl]-2-propynamide;

2-methyl-3-[[5-[(4-aminosulfonyl)phenyl]-6-(4-methoxyphenyl)-N-hydroxy-N-methyl-3-pyridyl]-2-propynamide;

2-methyl-3-[[6-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-N-hydroxy-N-methyl-3-pyridyl]-2-propynamide;

2-methyl-3-[[6-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-3-pyridyl]-2-propynamide;

2-methyl-3-[[5-[(4-aminosulfonyl)phenyl]-6-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-3-pyridyl]-2-propynamide;

2-methyl-3-[[5-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-6-phenyl-3-pyridyl]-2-propynamide;

2-methyl-3-[[5-(4-chlorophenyl)-N-hydroxy-N-methyl-6-[(4-methylsulfonyl)phenyl]-3-pyridyl]-2-propynamide;

2-methyl-3-[[4-[(4-aminosulfonyl)phenyl]-N-hydroxy-N-methyl-3-phenyl-2-furyl]-2-propynamide;

2-methyl-3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-N-hydroxy-N-methyl-2-furyl]-2-propynamide;

2-methyl-3-[[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-N-hydroxy-N-methyl-2-furyl]-2-propynamide;

2-methyl-3-[[5-[(4-aminosulfonyl)phenyl]-N-hydroxy-4-(4-methoxyphenyl)-N-methyl-2-furyl]-2-propynamide;

2-methyl-3-[[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-furyl]-2-propynamide;

2-methyl-3-[[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-N-hydroxy-N-methyl-2-furyl]-2-propynamide;

2-methyl-3-[[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-N-hydroxy-N-methyl-2-furyl]-2-propynamide;

2-methyl-3-[[4-[(4-methylsulfonyl)phenyl]-N-hydroxy-N-methyl-3-phenyl-2-furyl]-2-propynamide;

2-methyl-3-[[4-(4-chlorophenyl)-N-hydroxy-N-methyl-5-[(4-methylsulfonyl)phenyl]-2-furyl]-2-propynamide;

[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[5-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[5-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[5-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxy-phenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-3-benzamide;

[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-3-benzamide;

[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-2-benzamide;

[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-benzamide;

[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-benzamide;

[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-benzamide;

[3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-3-benzamide;

[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-3-benzamide;

[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-4-benzamide;

[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-benzamide;

[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-benzamide;

[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-benzamide;

[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-benzamide;

[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-N-hydroxy-N-methyl-2-benzamide;

[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-2-benzamide;

[4-(4-chlorophenyl)-3-(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-N-hydroxy-N-methyl-4-benzamide;

5-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[4-[(4-methylsulfonyl)phenyl]-5-cyclohexyl-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[5-(4-methylsulfonyl)phenyl]-4-cyclohexenyl-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

5-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-1,2,3-triazol-4-ylethanamide;

3-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

3-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

3-[5-(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

4-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

4-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

4-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

4-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

4-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

4-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

4-[5-cyclohexyl-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

4-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

3-[4-cyclohexenyl-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

3-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-N-hydroxy-N-methyl-3-cyclohexanamide;

N′-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-FLUOROPHENYL)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-FLUOROPHENYL)-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]ethyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-phenyl-5-isoxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-5-isoxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-5-isoxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-5-isoxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-5-isoxazolylmethyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-METHOXYPHENYL)-5-isoxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-FLUOROPHENYL)-5-isoxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-5-isoxazolyl]methyl-N′-hydroxyurea;

N′-[3-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-5-isoxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-phenyl-2-thienyll]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-2-thienyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-2-thienyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-2-thienyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-2-thienyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-METHOXYPHENYL)-2-thienyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-FLUOROPHENYL)-2-thienyl]methyl-N′-hydroxyurea;

N′-[3-[(4-methylsulfonyl)phenyl]-4-phenyl-5-thienyl]methyl-N′-hydroxyurea;

N′-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-5-thienyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-6-phenyl-3-pyridyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-6-(4-chlorophenyl)-3-pyridyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-6-(4-fluorophenyl)-3-pyridyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-6-(4-methoxyphenyl)-3-pyridyl]methyl-N′-hydroxyurea;

N′-[6-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-3-pyridyl]methyl-N′-hydroxyurea;

N′-[6-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-METHOXYPHENYL)-3-pyridyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-6-(3-chloro-4-FLUOROPHENYL)-3-pyridyl]methyl-N′-hydroxyurea;

N′-(5-[(4-methylsulfonyl)phenyl]-6-phenyl-3-pyridyl]methyl-N′-hydroxyurea;

N′-[5-(4-chlorophenyl)-6-[(4-methylsulfonyl)phenyl]-3-pyridyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-phenyl-2-furyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-2-furyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-2-furyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-furyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-2-furyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-furyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-FLUOROPHENYL)-2-furyl]methyl-N′-hydroxyurea;

N′-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-2-furyl]methyl-N′-hydroxyurea;

N′-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-furyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-METHOXYPHENYL)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-FLUOROPHENYL)-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[4-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]methyl-N′-hydroxyurea;

N′-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]methyl-N′-hydroxyurea;

3-[N′-[1-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-N′-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-2-propenyl]-N′-hydroxyurea;

3-N′-[1-[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-propenyl]-N′-hydroxyurea;

3-[N′-[1-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(-4-chlorophenyl)-1H-pyrazol-3-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[3-[(4-aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[3-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[1-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-(5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-(N′-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-phenyl-5-isoxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-5-isoxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-5-isoxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-5-isoxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-5-isoxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-5-isoxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-5-isoxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-5-isoxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[3-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-5-isoxazolyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-phenyl-2-thienyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-2-thienyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-2-thienyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-methoxyphenyl)-2-thienyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-methoxyphenyl)-2-thienyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)-2-thienyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(3-chloro-4-fluorophenyl)-2-thienyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[3-[(4-methylsulfonyl)phenyl]-4-phenyl-5-thienyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-5-thienyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-6-phenyl-3-pyridyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-6-(4-chlorophenyl)-3-pyridyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-6-(4-fluorophenyl)-3-pyridyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-6-(4-methoxyphenyl)-3-pyridyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[6-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-3-pyridyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[6-(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-3-pyridyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-6-(3-chloro-4-fluorophenyl)-3-pyridyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-methylsulfonyl)phenyl]-6-phenyl-3-pyridyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-(4-chlorophenyl)-6-[(4-methylsulfonyl)phenyl]-3-pyridyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-phenyl-2-furyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-4-[(4-aminosulfonyl)phenyl]-3-(4-chlorophenyl)-2-furyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-3-(4-fluorophenyl)-2-furyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-furyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-2-furyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-furyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-2-furyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-2-furyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

3-[N′-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-furyl]-1-methyl-2-propynyl]-N′-hydroxyurea;

N′-3-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[3-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[3-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazoly]phenyl]-N′-hydroxyurea;

N′-[4-[4-[(4-methylsulfonyl)phenyl]-5-phenyl-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[4-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[3-[5-[(4-methylsulfonyl)phenyl]-4-phenyl-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[3-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]phenyl]-N′-hydroxyurea;

N′-[3-[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[2-[1-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[2-[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[4-[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[4-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[3-[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[4-[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[4-[1-[(4-methylsulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[4-[5-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[3-[4-[(4-methylsulfonyl)phenyl]-3-phenyl-1H-pyrazol-1-yl]phenyl]-N′-hydroxyurea;

N′-[3-[4-(4-chlorophenyl)-3-[(4-methylsulfonyl)phenyl]-1H-pyrazol-1-yl]phenyl]-N′-hydroxyurea;

N′-5-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[4-[(4-methylsulfonyl)phenyl]-5-cyclohexyl-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[5-[(4-methylsulfonyl)phenyl]-4-cyclohexenyl-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[5-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]1,2,3-triazol-4-ylmethyl]-N′-hydroxyurea;

N′-[3-[4-[(4-aminosulfonyl)phenyl]-5-phenyl-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[3-[4-[(4-aminosulfonyl)phenyl]-5-(4-chlorophenyl)-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[3-[5-[(4-aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(4-chlorophenyl)-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(4-fluorophenyl)-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[4-5-[(4-aminosulfonyl)phenyl4-(3-chloro-4-methoxyphenyl)-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[4-[5-[(4-aminosulfonyl)phenyl]-4-(3-chloro-4-fluorophenyl)-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[4-[4-[(4-methylsulfonyl)phenyl]-5-cyclohexyl-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[4-[5-(4-chlorophenyl)-4-[(4-methylsulfonyl)phenyl]-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[3-[5-[(4-methylsulfonyl)phenyl]-4-cyclohexenyl-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[3-[4-(4-chlorophenyl)-5-[(4-methylsulfonyl)phenyl]-2-oxazolyl]cyclohexyl]-N′-hydroxyurea;

N′-[[1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea;

N′-[[1-[(4-aminosulfonyl)phenyl]-5-(4-fluorophenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea;

N′-[[1-[(4-aminosulfonyl)phenyl]-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea;

N′-[[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-methoxyphenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea;

N′-[[1-[(4-aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea;

N′-[[1-[(4-aminosulfonyl)phenyl]-5-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea;

N′-[[1-[4-(aminosulfonyl)phenyl]-5-(4-methylphenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea;

N′-[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]ethyl]-N′-hydroxyurea;

N′-[4-[1-[4-(aminosulfonyl)phenyl]-5-(4-methyl-3-chlorophenyl)-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[3-[1-[4-(aminosulfonyl)phenyl]-5-(4-methylphenyl)-1H-pyrazol-3-yl]phenyl]-N′-hydroxyurea;

N′-[5-[1-[4-(aminosulfonyl)phenyl]-5-(4-3-chlorophenyl)-1H-pyrazol-3-yl]-2-thienyl]-N′-hydroxyurea;

N′-[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl),-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea; and

4-(4-fluorophenyl)-N-hydroxy-N-methyl-5-[(4-methylsulfonyl)phenyl]-2-oxazolepropanamide.

The term “hydrido” denotes a single hydrogen atom (H). This hydridoradical may be attached, for example, to an oxygen atom to form ahydroxyl radical or two hydrido radicals may be attached to a carbonatom to form a methylene (—CH₂—) radical. Where used, either alone orwithin other terms such as “haloalkyl”, “alkylsulfonyl”, “alkoxyalkyl”,“aminoalkyl” and “hydroxyalkyl”, the term “alkyl” embraces linear orbranched radicals having one to about twenty carbon atoms or,preferably, one to about twelve carbon atoms. More preferred alkylradicals are “lower alkyl” radicals having one to about ten carbonatoms. Most preferred are lower alkyl radicals having one to about sixcarbon atoms. Examples of such radicals include methyl, ethyl, n-propyl,isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl,hexyl and the like. The term “alkenyl” embraces linear or branchedradicals having at least one carbon-carbon double bond of two to abouttwenty carbon atoms or, preferably, one to about twelve carbon atoms.More preferred alkenyl radicals are “lower alkenyl” radicals having twoto about six carbon atoms. Examples of alkenyl radicals include ethenyl,propenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The term“alkynyl” denotes linear or branched radicals having two to about twentycarbon atoms or, preferably, two to about twelve carbon atoms. Morepreferred alkynyl radicals are “lower alkynyl” radicals having two toabout ten carbon atoms. Most preferred are lower alkynyl radicals havingtwo to about six carbon atoms. Examples of such radicals includepropynyl, propargyl, butynyl, and the like. The terms “alkenyl”, and“lower alkenyl” embrace radicals having “cis” and “trans” orientations,or alternatively, “E” and “Z” orientations. The term “cycloalkyl”embraces saturated carbocyclic radicals having three to twelve carbonatoms. More preferred cycloalkyl radicals are “lower cycloalkyl”radicals having four to about eight carbon atoms. Examples of suchradicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.The term “cycloalkenyl”, embraces partially unsaturated carbocyclicradicals having three to twelve carbon atoms. More preferredcycloalkenyl radicals are “lower cycloalkenyl” radicals having four toabout eight carbon atoms. Examples of such radicals includecyclobutenyl, cyclopentenyl and cyclohexenyl. The term “halo” meanshalogens such as fluorine, chlorine, bromine or iodine. The term“haloalkyl” embraces radicals wherein any one or more of the alkylcarbon atoms is substituted with halo as defined above. Specificallyembraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. Amonohaloalkyl radical, for one example, may have either an iodo, bromo,chloro or fluoro atom within the radical. Dihalo and polyhaloalkylradicals may have two or more of the same halo atoms or a combination ofdifferent halo radicals. “Lower haloalkyl” embraces radicals having 1-6carbon atoms. Examples of haloalkyl radicals include fluoromethyl,difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl,difluorochloromethyl, dichlorofluoromethyl, difluoroethyl,difluoropropyl, dichloroethyl and dichloropropyl. The term “cyanoalkyl”embraces linear or branched alkyl radicals having one to about tencarbon atoms any one of which may be substituted with one or more cyanoradicals. More preferred cyanoalkyl radicals are “lower cyanoalkyl”radicals having one to six carbon atoms and one or more cyano radicals.Examples of such radicals include cyanomethyl, cyanoethyl, cyanopropyl,cyanobutyl and cyanohexyl. The term “hydroxyalkyl” embraces linear orbranched alkyl radicals having one to about ten carbon atoms any one ofwhich may be substituted with one or more hydroxyl radicals. Morepreferred hydroxyalkyl radicals are “lower hydroxyalkyl”, radicalshaving one to six carbon atoms and one or more hydroxyl radicals.Examples of such radicals include hydroxymethyl, hydroxyethyl,hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms “alkoxy” and“alkoxyalkyl” embrace linear or branched oxy-containing radicals eachhaving alkyl portions of one to about ten carbon atoms. More preferredalkoxy radicals are “lower alkoxy” radicals having one to six carbonatoms. Examples of such radicals include methoxy, ethoxy, propoxy,butoxy and tert-butoxy. The term “alkoxyalkyl” embraces alkyl radicalshaving one or more alkoxy radicals attached to the alkyl radical, thatis, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The “alkoxy”radicals may be further substituted with one or more halo atoms, such asfluoro, chloro or bromo, to provide haloalkoxy radicals. More preferredhaloalkoxy radicals are “lower haloalkoxy” radicals having one to sixcarbon atoms and one or more halo radicals. Examples of such radicalsinclude fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy,fluoroethoxy and fluoropropoxy. The term “aryl”, alone or incombination, means a carbocyclic aromatic system containing one, two orthree rings wherein such rings may be attached together in a pendentmanner or may be fused. The term “aryl” embraces aromatic radicals suchas phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Arylmoieties may also be substituted at a substitutable position with one ormore substituents selected independently from alkyl, alkoxyalkyl,alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl,alkoxy, aralkoxy, amino, halo, nitro, alkylamino, acyl, cyano, carboxy,aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl. The terms“heterocyclyl”, and “heterocyclo” embrace saturated, partiallyunsaturated and unsaturated heteroatom-containing ring-shaped radicals,where the heteroatoms may be selected from nitrogen, sulfur and oxygen.Examples of saturated heterocyclo radicals include saturated 3 to6-membered heteromonocylic group containing 1 to 4 nitrogen atoms (e.g.pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atomsand 1 to 3 nitrogen atoms (e.g. morpholinyl, etc.); saturated 3 to6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partiallyunsaturated heterocyclo radicals include dihydrothiophene, dihydropyran,dihydrofuran and dihydrothiazole. The term “heteroaryl” embracesunsaturated heterocyclo radicals. Examples of unsaturated heterocycloradicals, also termed “heteroaryl” radicals include unsaturated 3 to 6membered heteromonocyclic group containing 1 to 4 nitrogen atoms, forexample, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl,pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl,1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g.1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensedheterocyclo group containing 1 to 5 nitrogen atoms, for example,indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl,indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g.,tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3 to 6-memberedheteromonocyclic group containing an oxygen atom, for example, pyranyl,furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic groupcontaining a sulfur atom, for example, thienyl, etc.; unsaturated 3- to6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl(e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.)etc.; unsaturated condensed heterocyclo group containing 1 to 2 oxygenatoms and 1 to 3 nitrogen atoms (e.g. benzoxazolyl, benzoxadiazolyl,etc.); unsaturated 3 to 6-membered heteromonocyclic group containing 1to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl,thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl,1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclo groupcontaining 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g.,benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term alsoembraces radicals where heterocyclo radicals are fused with arylradicals. Examples of such fused bicyclic radicals include benzofuran,benzothiophene, and the like. Said “heterocyclo group” may also besubstituted at a substitutable position with one or more substituentsselected independently from alkyl, alkylaminoalkyl, carboxyalkyl,alkoxycarbonylalkyl, aminocarbonylalkyl, hydroxyl, alkoxy, aralkoxy,alkylaminoalkoxy, amino, halo, nitro, alkylamino, acyl, cyano, carboxy,aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl. The term“alkylthiol” embraces radicals containing a linear or branched alkylradical, of one to about ten carbon atoms attached to a divalent sulfuratom. More preferred alkylthio radicals are “lower alkylthio” radicalshaving alkyl radicals of one to six carbon atoms. Examples of such loweralkylthio radicals are methylthio, ethylthio, propylthio, butylthio andhexylthio. The term “alkylsulfinyl” embraces radicals containing alinear or branched alkyl radical, of one to ten carbon atoms, attachedto a divalent —S(═O)— radical. More preferred alkylsulfinyl radicals are“lower alkylsulfinyl” radicals having alkyl radicals of one to sixcarbon atoms. Examples of such lower alkylsulfinyl radicals includemethylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl. The term“sulfonyl”, whether used alone or linked to other terms such asalkylsulfonyl, denotes respectively divalent radicals —SO₂—.“Alkylsulfonyl”, embraces alkyl radicals attached to a sulfonyl radical,where alkyl is defined as above. More preferred alkylsulfonyl radicalsare “lower alkylsulfonyl” radicals having one to six carbon atoms.Examples of such lower alkylsulfonyl radicals include methylsulfonyl,ethylsulfonyl and propylsulfonyl. The “alkylsulfonyll” radicals may befurther substituted with one or more halo atoms, such as fluoro, chloroor bromo, to provide haloalkylsulfonyl radicals. The terms “sulfamyl”,“aminosulfonyl” and “sulfonamidyl” denote NH₂O₂S—. The term “aralkyl”embraces aryl-substituted alkyl radicals. Preferred aralkyl radicals are“lower aralkyl” radicals where the alkyl radicals are of 1-6 carbons.Examples of such lower aralkyl radiclas include benzyl, diphenylmethyl,triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in saidaralkyl may be additionally substituted with halo, alkyl, alkoxy,halkoalkyl and haloalkoxy. The terms benzyl and phenylmethyl areinterchangeable. The term “cycloalkylalkyl” embracescycloalkyl-substituted alkyl radicals. Preferred cycloalkylalkylradicals are “lower cycloalkylalkyl” radicals where the alkyl radicalsare of 1-6 carbons. Examples of such radicals include cyclohexylmethyl,cyclopentylmethyl, cyclobutylmethyl, cyclohexylethyl, andcyclopentylpropyl. The term “heterocycloalkyl” embracesheterocyclo-substituted alkyl radicals. Preferred heterocycloalkylradicals are “lower heterocycloalkyl” radicals where the alkyl radicalsare of 1-6 carbons and the heterocyclo radicals have 5- or 6-members.Examples of such radicals include triazolylmethyl, triazolylethyl,thienylmethyl, furylethyl, and piperidinomethyl. The heterocyclo in saidheterocycloalkyl may be additionally substituted with halo, alkyl,alkoxy, halkoalkyl and haloalkoxy. The term “acyl” denotes a radicalprovided by the residue after removal of hydroxyl from an organic acid.Examples of such acyl radicals include alkanoyl and aroyl radicals. Thealkanoyl radicals may be substituted or unsubstituted, such as formyl,acetyl, propionyl (propanoyl), butanoyl (butyryl), isobutanoyl(isobutyryl), valeryl (pentanoyl), isovaleryl, pivaloyl, hexanoyl or thelike. The terms “carboxy” or “carboxyl”, whether used alone or withother terms, such as “carboxyalkyl”, denotes —CO₂H. The terms“carboxyalkyl” embrace radicals having a carboxy radical as definedabove, attached to an alkyl radical. More preferred carboxyalkylradicals are “lower carboxyalkyl” radicals having alkyl portions of 1-6carbons. The term “carbonyl”, whether used alone or with other terms,such as “alkoxycarbonyl”, denotes —(C═O)—. The term “alkoxycarbonyl”means a radical containing an alkoxy radical, as defined above, attachedvia an oxygen atom to a carbonyl radical. Examples of such“alkoxycarbonyl” ester radicals include substituted or unsubstitutedmethoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl andhexyloxycarbonyl. The terms “alkylcarbonyl”, “arylcarbonyl” and“aralkylcarbonyl” include radicals having alkyl, aryl and aralkylradicals, as defined above, attached via an oxygen atom to a carbonylradical. Examples of such radicals include substituted or unsubstitutedmethylcarbonyl, ethylcarbonyl, phenylcarbonyl and benzylcarbonyl. Theterm “aminoalkyl”, embraces alkyl radicals substituted with aminoradicals. More preferred are “lower aminoalkyl” radicals. Examples ofsuch radicals include aminomethyl, aminoethyl, and the like. The term“alkylamino” denotes amino groups which have been substituted with oneor two alkyl radicals. More preferred are “lower N-alkylaminol” and“lower N,N-dialkylamino”. Examples of such radicals includeN-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino and thelike. The term “arylamino” denotes amino groups which have beensubstituted with one or more aryl radicals. Examples of such radicalsinclude N-phenylamino and N-naphthylamino. The “arylamino” radicals maybe further substituted on the aryl ring portion of the radical. The term“alkylaminoalkyl”, denotes aminoalkyl groups which have been substitutedwith one or two alkyl radicals, as defined above. More preferred are“lower N-alkylaminoalkyl”, and “lower N,N-dialkylaminoalkyl”, wherelower alkyl is defined above. Examples of such radicals includeN-methylaminoethyl, N-ethylaminopropyl, N,N-dimethylaminoethyl,N,N-diethylaminomethyl, and the like. The term “arylaminoalkyl” denotesaminoalkyl groups which have been substituted with one or more arylradicals, as defined above. More preferred is “lower N-arylaminoalkyl”,where lower aminoalkyl is defined above. Examples of such radicalsinclude N-phenylaminoethyl and N-phenylaminopropyl. The “arylaminoalkyl”radicals may be further substituted on the aryl ring portion of theradical. The term “aminocarbonyl” denotes an amide group of the formula—C(═O)NH₂.

When the above radicals are included as linker moiety “Y” in FormulasI-III, such radicals are divalent radicals. For terms such as aralkyl,and heterocycloalkyl, the moiety may be linked to “A” and “R³”, througha divalent alkyl radical, or through the alkyl radical at one end andthe aryl or heteroaryl portion at the other. The use of heterocyclo andaryl moieties includes divalent attachment at substitutable sites.

The present invention comprises a pharmaceutical composition comprisinga therapeutically-effective amount of a compound of Formulas I-III inassociation with at least one pharmaceutically-acceptable carrier,adjuvant or diluent.

The present invention also comprises a method of treating inflammationor inflammation-associated disorders in a subject, the method comprisingtreating the subject having or susceptible to such inflammation ordisorder, with a therapeutically-effective amount of a compound ofFormulas I-III. The method includes prophylactic or chronic treatment,especially in the case of arthritis and other inflammatory conditionswhich can lead to deterioration in the joints.

Also included in the family of compounds of Formula I are thestereoisomers and tautomers thereof. Compounds of the present inventioncan possess one or more asymmetric carbon atoms and are thus capable ofexisting in the form of optical isomers as well as in the form ofracemic or nonracemic mixtures thereof. Accordingly, some of thecompounds of this invention may be present in racemic mixtures which arealso included in this invention. The optical isomers can be obtained byresolution of the racemic mixtures according to conventional processes,for example by formation of diastereoisomeric salts by treatment with anoptically active acid or base. Examples of appropriate acids aretartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric andcamphorsulfonic acid and then separation of the mixture ofdiastereoisomers by crystallization followed by liberation of theoptically active bases from these salts. A different process forseparation of optical isomers involves the use of a chiralchromatography column optimally chosen to maximize the separation of theenantiomers. Still another available method involves synthesis ofcovalent diastereoisomeric molecules by reacting an amine functionalityof precursors to compounds of Formula I with an optically pure acid inan activated form or an optically pure isocyanate. Alternatively,diastereomeric derivatives can be prepared by reacting a carboxylfunctionality of precursors to compounds of Formula I with an opticallypure amine base. The synthesized diastereoisomers can be separated byconventional means such as chromatography, distillation, crystallizationor sublimation, and then hydrolyzed to deliver the enantiomerically purecompound. The optically active compounds of Formula I can likewise beobtained by utilizing optically active starting materials. These isomersmay be in the form of a free acid, a free base, an ester or a salt.

Also included in the family of compounds of Formula I are thepharmaceutically-acceptable salts thereof. The term“pharmaceutically-acceptable salts” embraces salts commonly used to formalkali metal salts and to form addition salts of free acids or freebases. The nature of the salt is not critical, provided that it ispharmaceutically-acceptable. Suitable pharmaceutically-acceptable acidaddition salts of compounds of Formula I may be prepared from aninorganic acid or from an organic acid. Examples of such inorganic acidsare hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuricand phosphoric acid. Appropriate organic acids may be selected fromaliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclo,carboxylic and sulfonic classes of organic acids, example of which areformic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic,tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic,aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic,p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic),methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic,toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic,cyclohexylaminosulfonic, algenic, β-hydroxybutyric, salicylic,galactaric and galacturonic acid. Suitable pharmaceutically-acceptablebase addition salts of compounds of Formula I include metallic saltsmade from aluminum, calcium, lithium, magnesium, potassium, sodium andzinc or organic salts made from N,N′-dibenzylethylenediamine,chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine(N-methylglucamine) and procaine. All of these salts may be prepared byconventional means from the corresponding compound of Formula I byreacting, for example, the appropriate acid or base with the compound ofFormula I.

General Synthetic Procedures

The compounds of the invention can be synthesized according to thefollowing procedures of Schemes I-XXIV, wherein the R¹-R⁶ substituentsare as defined for Formula I-III, above, except where further noted.

Synthetic Scheme I shows the preparation of amide derivatives 3, whereone of Z or W is a leaving group.

A substituted hydroxylamine or equivalent 2, is dissolved in anhydroussolvent such as THF or methylene chloride. A solution of sulfonylphenylderivative 1 in anhydrous DMF is added and stirred at about 0° C. toprovide the sulfonylphenyl amide derivatives 3. In addition,hydroxydithiocarbamates can be prepared by the methods described in U.S.Pat. No. 5,298,521, and N-hydroxyamides can be prepared by theprocedures described in U.S. Pat. No. 5,051,518, both of which areincorporated by reference.

Synthetic Scheme II shows the preparation of pyrazole compounds embracedby Formula I where R is Z, (as defined in Scheme I) and Ra is a radicaldefined above for the substituents optionally substituted on A. In step1, ketone 4 is treated with a base, preferably NaOMe or NaH, and anester, or ester equivalent, to form the intermediate diketone 5 (in theenol form) which is used without further purification. In step 2,diketone 5 in an anhydrous protic solvent, such as absolute ethanol oracetic acid, is treated with the hydrochloride salt or the free base ofa substituted hydrazine at reflux to afford a mixture of pyrazoles 6 and7. Recrystallization from diethyl ether/hexane or chromatography affords6 usually as a solid. Similar pyrazoles can be prepared by methodsdescribed in U.S. Pat. Nos. 4,146,721, 5,051,518, 5,134,142 and4,914,121 which are incorporated by reference.

Scheme III shows the four step procedure for forming pyrazoles 11 of thepresent invention (where Rb is alkyl) from ketones 8. In step 1, ketone8 is reacted with a base, such as lithium bis(trimethylsilyl)amide orlithium diisopropylamide (LDA) to form the anion. In step 2, the anionis reacted with an acetylating reagent to provide diketone 9. In step 3,the reaction of diketone 9 with hydrazine or a substituted hydrazine,gives pyrazole 10. In step 4, the pyrazole 10 is oxidized with anoxidizing reagent, such as Oxone® (potassium peroxymonosulfate),3-chloroperbenzoic acid (MCPBA) or hydrogen peroxide, to give a mixtureof the desired 3-(alkylsulfonyl)phenyl-pyrazole 11 and the5-(alkylsulfonyl)phenyl-pyrazole isomer. The desired pyrazole 11,usually a white or pale yellow solid, is obtained in pure form either bychromatography or recrystallization.

Alternatively, diketone 9 can be formed from ketone 8 by treatment witha base, such as sodium hydride, in a solvent, such as dimethylformamide,and further reacting with a nitrile to form an aminoketone. Treatment ofthe aminoketone with acid forms the diketone 9. Similar pyrazoles can beprepared by methods described in U.S. Pat. No. 3.984,431 which isincorporated by reference.

Diaryl/heteroaryl thiophenes (where T is S, and R^(b) is alkyl) can beprepared by the methods described in U.S. Pat. Nos. 4,427,693,4,302,461, 4,381,311, 4,590,205, and 4,820,827, and PCT documents WO95/00501 and WO94/15932, which are incorporated by reference. Similarpyrroles (where T is N), furanones and furans (where T is O) can beprepared by methods described in PCT documents WO 95/00501 andWO94/15932.

Diaryl/heteroaryl oxazoles can be prepared by the methods described inU.S. Pat. Nos. 3,743,656, 3,644,499 and 3,647,858, and PCT documents WO95/00501 and WO94/15932, which are incorporated by reference.

Diaryl/heteroaryl isoxazoles can be prepared by the methods described inPCT documents WO92/05162, and WO92/19604, and European Publication EP26928 which are incorporated by reference. Sulfonamides 27 can be formedfrom the hydrated isoxazole 26 in a two step procedure. First, hydratedisoxazole 26 is treated at about 0° C. with two or three equivalents ofchlorosulfonic acid to form the corresponding sulfonyl chloride. In steptwo, the sulfonyl chloride thus formed is treated with concentratedammonia to provide the sulfonamide derivative 27.

Scheme VII shows the three step preparation of the substitutedimidazoles 32 of the present invention. In step 1, the reaction ofsubstituted nitriles (R¹CN) 28 with primary phenylamines 29 in thepresence of alkylaluminum reagents such as trimethylaluminum,triethylaluminum, dimethylaluminum chloride, diethylaluminum chloride inthe presence of inert solvents such as toluene, benzene, and xylene,gives amidines 30. In step 2, the reaction of amidine 30 with2-haloketones (where X is Br or Cl) in the presence of bases, such assodium bicarbonate, potassium carbonate, sodium carbonate, potassiumbicarbonate or hindered tertiary amines such asN,N′-diisopropylethylamine, gives the 4,5-dihydroimidazoles 31 (whereR^(c) is hydroxyl, R^(d) is hydrido and R^(e) is alkyl, halo orhydrido). Some of the suitable solvents for this reaction areisopropanol, acetone and dimethylformamide. The reaction may be carriedout at temperatures of about 20° C. to about 90° C. In step 3, the4,5-dihydroimidazoles 31 may be dehydrated in the presence of an acidcatalyst such as 4-toluenesulfonic acid or mineral acids to form the1,2-disubstituted imidazoles 32 of the invention. Suitable solvents forthis dehydration step are e.g., toluene, xylene and benzene.Trifluoroacetic acid can be used as solvent and catalyst for thisdehydration step.

In some cases (e.g., where YR=methyl or phenyl) the intermediate 31 maynot be readily isolable. The reaction, under the conditions describedabove, proceeds to give the targeted imidazoles directly.

Similarly, imidazoles can be prepared having the sulfonylphenyl moietyattached at position 2 and R¹ attached at the nitrogen atom atposition 1. Diaryl/heteroaryl imidazoles can be prepared by the methodsdescribed in U.S. Pat. Nos. 4,822,805, and PCT document WO 93/14082,which are incorporated by reference.

The subject imidazole compounds 39 of this invention may be synthesizedaccording to the sequence outlined in Scheme VIII. Aldehyde 33 may beconverted to the protected cyanohydrin 34 by reaction with atrialkylsilyl cyanide, such as trimethylsilyl cyanide (TMSCN) in thepresence of a catalyst such as zinc iodide (ZnI₂) or potassium cyanide(KCN). Reaction of cyanohydrin 34 with a strong base followed bytreatment with benzaldehyde 35 (where R² is alkyl) and using both acidand base treatments, in that order, on workup gives benzoin 36. Examplesof strong bases suitable for this reaction are lithium diisopropylamide(LDA) and lithium hexamethyldisilazane. Benzoin 36 may be converted tobenzil 37 by reaction with a suitable oxidizing agent, such as bismuthoxide or manganese dioxide, or by a Swern oxidation using dimethylsulfoxide (DMSO) and trifluoroacetic anhydride. Benzil 37 may beobtained directly by reaction of the anion of cyanohydrin 34 with asubstituted benzoic acid halide. Any of compounds 36 and 37 may be usedas intermediates for conversion to imidazoles 38 (where R² is alkyl)according to chemical procedures known by those skilled in the art anddescribed by M. R. Grimmett, “Advances in Imidazole Chemistry” inAdvances in Heterocyclic Chemistry, 12, 104 (1970). The conversion of 37to imidazoles 38 is carried out by reaction with ammonium acetate and anappropriate aldehyde (RYCHO) in acetic acid. Benzoin 36 may be convertedto imidazoles 38 by reaction with formamide. In addition, benzoin 36 maybe converted to imidazoles by first acylating with an appropriate acylgroup (RYCO—) and then treating with ammonium hydroxide. Those skilledin the art will recognize that the oxidation of the sulfide (where R² ismethyl) to the sulfone may be carried out at any point along the waybeginning with compounds 35, and including oxidation of imidazoles 38,using, for examples, reagents such as hydrogen peroxide in acetic acid,m-chloroperoxybenzoic acid (MCPBA) and potassium peroxymonosulfate(OXONE®).

Diaryl/heteroaryl imidazoles can be prepared by the methods described inU.S. Pat. Nos. 3,707,475, 4,686,231, 4,503,065, 4,472,422, 4,372,964,4,576,958, 3,901,908, European publication EP 372,445, and PCT documentWO 95/00501, which are incorporated by reference.

Diaryl/heteroaryl cyclopentenes can be prepared by the methods describedin U.S. Pat. No. 5,344,991, and PCT document WO 95/00501, which areincorporated by reference.

Similarly, Synthetic Scheme X shows the procedure for the preparation of1,2-diarylbenzene antiinflammatory agents 47 from 2-bromo-biphenylintermediates 46 (prepared similar to that described in Synthetic SchemeIX) and the appropriate substituted phenylboronic acids. Using acoupling procedure similar to the one developed by Suzuki et al. [Synth.Commun., 11, 513 (1981)], intermediates 46 are reacted with the boronicacids in toluene/ethanol at reflux in the presence of a Pd° catalyst,e.g. , tetrakis (triphenylphosphine) palladium (0), and 2M sodiumcarbonate to give the corresponding 1,2-diarylbenzene antiinflammatoryagents 47 of this invention.

Diaryl/heteroaryl thiazoles can be prepared by the methods described inU.S. Pat. No. 4,051,250, 4,632,930, European Application EP 592, 664,and PCT document WO 95/00501, which are incorporated by reference.Isothiazoles can be prepared as described in PCT document WO 95/00501.

Diaryl/heteroaryl pyridines can be prepared by the methods described inU.S. Pat. Nos. 5,169,857, 4,011,328, and 4,533,666, which areincorporated by reference. For example, Synthetic Scheme XII shows theprocedure used to prepare 3-alkylcarbonylaminoalkyl pyridineantiinflammatory agents 53, 3-haloalkyl pyridine antiinflammatory agents55, 3-hydroxyalkyl pyridine antiinflammatory agents 56, heteroatomsubstituted 3-alkyl pyridine antiinflammatory agents 58 and3-aryloxyalkyl pyridine antiinflammatory agents 59 from thecorresponding carbonitriles 51 (where R^(f) is hydrido, halo, alkoxy,haloalkoxy, aryl, alkylthio, alkylamino, aralkoxy, azido or allyloxy).The 3-alkylcarbonylaminoalkyl pyridine antiinflammatory agents 53 (whereR′ is alkyl) are prepared in a two step procedure from the carbonitriles51. In step one, the carbonitrile 51 is reduced using reducing agents,such as diisobutyl aluminum hydride (DIBAL) in a solvent such as tolueneor boranes in a solvent such as tetrahydrofuran. at room temperature orreflux to form the aminoalkyl pyridines 52. Additional reducing reagentmay be added to the solution. In step two, an acid chloride is added tothe aminoalkyl pyridines 52 in a solvent such as ethyl ether ortetrahydrofuran and stirred to form the alkylcarbonylaminoalkylpyridines 53. The 3-haloalkyl pyridine antiinflammatory agents 55 areprepared in a two step procedure from the carbonitriles 51. In step one,the carbonitriles 51 are reduced using agents, such as diisobutylaluminum hydride (DIBAL) in a solvent such as toluene, at roomtemperature to form the aldehydes 54. The 3-hydroxyalkyl pyridines 56also can be isolated from this reaction. In step two, a halogenatingagent, such as diethylamino sulfur trifluoride (DAST) is added to thealdehyde 54 to form the haloalkyl pyridines 55. Reduction of aldehydes54 with agents such as diisobutyl aluminum hydride (DIBAL) followed bymethanol and water in methanol to yield the 3-hydroxyalkyl pyridines 56.Compound 56 is convertible to alkoxyalkyl and aralkoxyalkyl compounds 59by sequential treatment first with a base and then with an alkyl oraralkyl halide. An example of a suitable base is sodium hydride.Examples of alkyl and aralkyl halides are methyl iodide and benzylchloride. Alternatively, compound 56 may be converted to the haloalkylcompound 57 using a suitable halogenating agent, such as thionylchloride. Under such circumstances, the hydrochloride salt may beisolated. This in turn may be converted to compounds 58 by reaction withthe appropriate alcohol, thiol, or amine. It may be advantageous tocarry out this reaction in the presence of a base. Examples of suitablealcohols are methanol, ethanol, benzyl alcohol and phenol. Examples ofsuitable thiols are n-butyl mercaptan, benzylthiol and thiophenol.Examples of suitable amines are dimethylamine, benzylamine,N-methylbenzylamine, aniline, N-methylaniline and diphenylamine.Examples of suitable bases are sodium hydride and potassium carbonate.Alternatively, amines are accessible by reaction of aldehyde 54 with aprimary or secondary amine in the presence of a reducing agent. Examplesof suitable primary amines are methyl amine and ethylamine. An exampleof a suitable secondary amine is dimethylamine. Suitable reducing agentsinclude sodium cyanoborohydride and sodium borohydride.

Scheme XIII shows a method to form the alkylsulfonylphenyl substitutedcompounds 61 of the current invention by oxidation of alkylthio oralkylsulfinyl derivatives 60. Aqueous hydrogen peroxide (30%) is addedto a suspension of a (methylthio)phenyl substituted compound 60 inacetic acid. The mixture is stirred while heating to about 100° C. forabout 2 hours. Alternatively, m-chloroperoxybenzoic acid (MCPBA), andother oxidizing agents [potassium peroxymonosulfate (OXONE®)] can beused to form the sulfonyl radicals 61.

Synthetic Scheme XIV shows the three step procedure used to preparesulfonamide antiinflammatory agents 63 and the two step procedure usedto prepare fluoromethyl sulfone antiinflammatory agents 64 from theircorresponding methyl sulfones 62. In step one, THF solutions of themethyl sulfones 62 at −78° C. are treated with an alkyllithium reagent,e.g., methyllithium, n-butyllithium, etc. In step two, the anionsgenerated in step one are treated with an organoborane, e.g.,triethylborane, tributylborane, etc., at −78° C. then allowed to warm toambient temperature prior to stirring at reflux. In step three, anaqueous solution of sodium acetate and hydroxylamine-O-sulfonic acid isadded to provide the corresponding sulfonamide antiinflammatory agents63 of this invention. As an alternative to the borane chemistry found instep two above, the base treated sulfone is reacted with an alkylsilane,such as (iodomethyl)trimethylsilane or (chloromethyl)trimethylsilane, atroom temperature to give a silylalkylsulfone. The silylalkylsulfone isconverted to a sulfinic acid salt by heating to about 90° C. withtetrabutylammoniumfluoride. Treatment proceeds as in step three above toproduce the sulfonamide.

Alternatively, the anion solutions generated in step one may be warmedto 0° C. and treated with N-fluorodibenzenesulfonamide to provide thecorresponding fluoromethyl sulfone antiinflammatory agents 64 of thisinvention.

Synthetic Scheme XV shows a method of making the pyrazole ureas 69 ofthe present invention. In step 1, the dione 66 is formed from ketone 65through the addition of a base, such as lithium bis(trimethylsilyl)amideor lithium diisopropylamide (LDA), followed by reacting with anappropriate acetylating reagent, such as (CO₂CH₃)₂. Treatment of thedione 66 with a phenylhydrazide yields the pyrazole ester 67. Thepyrazole ester 67 is reduced to the alcohol 68 by treatment with baseand borane in THF. In step four, the alcohol 68 is reacted withtriphenylphosphine, an alkyl azodicarboxylate (e.g. diisopropylazodicarboxylate (DIAD) and diethyl azodicarboxylate (DEAD)), andbis(phenoxycarbonyl) hydroxylamine [prepared by the method of Stewartand Brooks, J.Org.Chem., 57, 5020-23 (1992)] in a solvent such astetrahydrofuran (THF) at about 0° C. to room temperature. Aminolysiswith ammonium hydroxide yields the anti-inflammatory ureas 69 of thepresent invention.

Scheme XVI shows a procedure for forming an alkynyl oxazole 74 (where R²is amino), similar to that shown in Scheme V above. The ketonesulfonamide 71 is formed from ketone 70 through chlorosulfonation andammonolysis with ammonium hydroxide in a solvent such as acetone. Theketone sulfonamide 71 is halogenated, such as with HBr in acetic acidand bromine, to form the haloketone sulfonamide 72. Substitution withbutynoic acid in the presence of K₂CO₃, a crown ether such as 18-Crown-6and dimethylacetamide (DMA) yields the alkynyl ketoester 73. Conversionof the alkynyl ester 73 to the alkynyl oxazole 74 proceeds as previouslydescribed in Scheme V.

Synthetic Scheme XVII shows the procedures for formingheterocycloalkynyl ureas 76, heterocyclotriazole ureas 77 andheterocycloalkyl ureas 78, from the corresponding alkynes 74. Thealkynes 74, such as formed in Scheme XVI, are halogenated, such as withN-bromosuccinimide (NBS) and 2,2′-azobis(2-methylpropionitrile (AIBN),to form the haloalkynes 75. The alkynyl halide 75 can be converted intothe urea by a three step procedure. In the first step, the halide 75 istreated with bis(phenoxycarbonyl)hydroxylamine. Aminolysis with ammoniumhydroxide yields the ureas 76 of the present invention. The alkynylureas 76 can be converted to heterocyclo-containing ureas 77, such as bytreatment with azidotrimethylsilane, followed by acid. Alternatively,the alkynyl ureas 76 can be reduced, such as with hydrogen in thepresence of catalyst (e.g., palladium) to yield the heterocycloalkylureas 78.

Scheme XVIII shows a method of forming the alkenyl ureas 79, and diols80 of the present invention from the appropriate alkynyl ureas 76. InStep one, treatment with diimide reduces the alkynyl ureas 77 to thealkenyl ureas 79. oxidation of the alkenyl urea 79, such as with osmiumtetraoxide and hydrogen peroxide, yields the diols 80 of the presentinvention.

Scheme XIX shows the preparation of ureas 83 and amides 85antiinflammatory agents of the present invention. Esters 81 (where R^(i)is alkyl, as provided for in WO94/27980) can be converted to thealcohols 82 by treatment with a reducing agent, such as DIBAL-H.Alcohols 82 can be directly converted to the protected urea by treatingwith triphenylphosphine, diethyl azodicarboxylate (DEAD), andN,O-bis(phenoxycarbonyl)hydroxylamine. Aminolysis with ammoniumhydroxide yields the urea 83. Alternatively, the esters 81 can behydrolyzed to the acids 84 with base such as LiOH. Amides 85 are formedfrom the acid 84 by treatment with oxalyl chloride to form thecorresponding acid chlorides, followed by substitution with thehydroxylamines.

Scheme XX shows the preparation of the antiinflammatory amides 88 of thepresent invention. Base treatment of ester 86, such as with sodiumhydride, followed by addition of an aralkyl halide or heteroaralkylhalide forms the ester 87. Formation of the amide 88 from the esters 87occurs in a three step procedure. Treatment with base, such as lithiumhydroxide, and thionyl chloride yields the acid chloride. Addition of ahydroxylamine yields the amide 88.

Scheme XXI shows an alternative preparation of the alkynyl alcohol 90and alkynyl halides 91 previously described in Scheme XVII. Cyclichalides 89 can be converted to the substituted alkynyl alcohols 90 byreacting an alkynyl alcohol with the halides 89 in the presence of baseand bis(triphenylphosphine)palladium(II)chloride. The alkynyl alcohol 90can be converted to the alkynyl halide 91 by treatment withtriphenoxyphosphonium methyliodide.

Additional antiinflammatory agents containing various substituted alkylspacer radicals including hydroxyalkylureas 96 and aminoalkylureas 98,can be prepared from ketones 92, by the procedures shown in Scheme XXII.The ketones 92 are halogenated to form haloketones 93, such as bytreatment with NBS in the presence of AIBN. Treatment of the halides 93with bis(phenoxycarbonyl)hydroxylamine in the presence of base, such assodium hydride, generates the protected (ketoalkyl)hydroxylamines 94.The protected (ketoalkyl)hydroxylamines 94 can be converted to theprotected (hydroxyalkyl)hydroxylamines 95 by reducing the carbonyl, suchas with sodium borohydride. Deprotection, such as with ammoniumhydroxide, yields the hydroxyalkylureas 96. Amination of the protected(ketoalkyl)hydroxylamines 94 by reaction with ammonium acetate andsodium cyanoborohydride in the presence of acetic acid generates theprotected (aminoalkyl)hydroxylamines 97. Deprotection, such as withammonium hydroxide, yields the aminoalkylureas 98.

Scheme XXIII shows a method for preparing oxazoles 103. A solution ofaldehyde 99 and zinc iodide in an organic solvent such asdichloromethane is treated with trimethylsilylcyanide to give thetrimethylsilyl cyanohydrin. The trimethylsilyl cyanohydrin is added to asolution of R¹ magnesium bromide in diethyl ether while maintaining thetemperature between 25-35° C. to give the benzoin 100. The benzoin 100,pyridine, and acid chloride are reacted at room temperature to yield thebenzoin ester 101. Addition of ammonium acetate to the benzoin ester 101yields the oxazole 103. Alternatively, the hydroxy-oxazoline 102 isisolated. Dehydration of the hydroxy-oxazoline 102 yields the oxazoles103. By reversing the positions of R¹ and the phenyl group in benzoin100, oxazoles can be prepared where R¹ is at position 4.

Scheme XXIV shows a method of preparing oxazolylbenzenesulfonamides 106of the present invention. The oxazole 104 is stirred with chlorosulfonicacid at about 5° C. to give the sulfonyl chlorides 105. The sulfonylchloride 105 is reacted at about 5° C. with ammonium hydroxide to givethe sulfonamides 106 of the current invention.

The following examples contain detailed descriptions of the methods ofpreparation of compounds of Formulas I-III. These detailed descriptionsfall within the scope, and serve to exemplify, the above describedGeneral Synthetic Procedures which form part of the invention. Thesedetailed descriptions are presented for illustrative purposes only andare not intended as a restriction on the scope of the invention. Allparts are by weight and temperatures are in Degrees centigrade unlessotherwise indicated. All compounds showed NMR spectra consistent withtheir assigned structures.

EXAMPLE 1

Step 1. Preparation of Methyl-4-(4-chlorophenyl)-2,4-dioxobutanoate.

Dimethyl oxalate (15.27 g, 0.129 mol) and 4′-chloroacetophenone (20.0 g,0.129 mol) were diluted with methanol (300 mL) and sodium methoxide (25wt % in methanol, 70 mL) was added in one portion. The reaction wasstirred at room temperature for 16 hours (the reaction became aninsoluble mass during this time). The solid was mechanically broken up,hydrochloric acid (conc. 70 mL) was added, and the white suspension wasstirred vigorously at room temperature for 1 hour. The suspension wascooled to 0° C. and held for 0.5 hour. The solid was filtered, and thefilter cake was washed with cold water (100 mL). Upon drying,methyl-4-[4-(chloro)phenyl]-2,4-dioxobutanoate was obtained (16.94 g,54.4%) as the enol: mp 108.5-110.5° C. ¹H NMR (CDCl₃/300 MHz) δ 7.94 (d,J=8.66 Hz, 2H), 7.48 (d, J=8.66 Hz, 2H), 7.04 (s, 1H), 3.95 (s, 3H),3.48 (s, 1H).

Step 2. Preparation of Methyl1-(4-aminosulfonylphenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylate

Methyl-4-[4-(chloro)phenyl]-2,4-dioxobutanoate from Step 1 (5.0 g, 20.78mmol) was added to 4-sulfonamidylphenyl hydrazine hydrochloride (5.11 g,22.86 mmol) and methanol (50 mL). The reaction vessel was heated toreflux and held for 16 hours. A precipitate formed overnight. Thesuspension was cooled to 0° C., held for 0.5 hour, filtered and washedwith cold water to provide, after air drying, 7.91 g, 91% of crudepyrazole. Recrystallization of 3.50 g from boiling ethanol yielded 3.14g (90%) of pure methyl1-(4-aminosulfonylphenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylate:mp 227° C.; ¹H NMR (CDC l₃/300 MHz) δ 7.91 (d, J=8.86 Hz, 2H), 7.44 (d,J=8.86 Hz, 2H), 7.33 (d, J=8.66 Hz, 2H), 7.14 (d, J=8.66 Hz, 2H), 7.03(s, 1H), 3.96 (s, 3H). Mass Spectrum, MH+=392. Anal. Calc'd forC₁₇H₁₄N₃O₄ClS: C, 52.11; H, 3.60; N, 10.72; Cl, 9.05; S, 8.18. Found: C,52.07; H, 3.57; N, 10.76; Cl, 9.11; S, 8.27.

Step 3. Preparation of1-(4-aminosulfonylphenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylicAcid

Methyl1-(4-aminosulfonylphenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylatefrom Step 2 (1.0 g, 2.66 mmol) was added to tetrahydrofuran (20 mL).Aqueous sodium hydroxide (2.5 N, 2.7 mL) and water (2.5 mL) were added,and the suspension was heated to reflux and held for 16 hours. Thesolids dissolved during this time. The reaction was cooled to roomtemperature, and hydrochloric acid solution (1 N, 11 mL) was added. Theaqueous suspension was extracted with methylene chloride (2×20 mL). Thecombined organic solution was dried over anhydrous magnesium sulfate,filtered, and concentrated in vacuo to an oil. Trituration with 30 mL ofdichloromethane yielded, upon filtration and drying,1-(4-aminosulfonylphenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylicacid (0.90 g (94%)) as a white solid: mp 126-128° C.

Step 4. Preparation of4-[5-(4-chlorophenyl)-3-hydroxymethyl-1H-pyrazol-1-yl]benzenesulfonamide.

4-[4-(Aminosulfonyl)phenyl-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylicacid from Step 3 (3.8 g, 10 mmol) and tetrahydrofuran (100 mL) wasstirred at room temperature during the dropwise addition of 1.0 Mborane-tetrahydrofuran complex (30 mL, 30 mmol). The mixture was heatedto reflux for 16 hours. The solution was cooled and methanol was addeddropwise until gas evolution ceased. Ethyl acetate (100 mL) was addedand the solution was washed with 1N hydrochloric acid, brine, and sat.aq. sodium bicarbonate solution, dried over magnesium sulfate, filteredand concentrated. The resultant material was recrystallized fromethanol:water to yield4-[5-(4-chlorophenyl)-3-hydroxymethyl-1H-pyrazol-1-yl]benzenesulfonamide(2.6 g, 71%) as a white solid: mp 192-194° C.; ¹H NMR (DMSO-d₆/300 MHz)δ 7.81 (d, J=8.7 Hz, 2H), 7.46 (d, J=8.4 Hz, 2H), 7.42 (brs, 2H), 7.40(d, J=8.7 Hz, 2H), 7.26 (d, J=8.4 Hz, 2H), 6.63 (s, 1H), 5.35 (t, J=8.0Hz, 1H), 4.50 (d, J=8.0 Hz, 2H). Anal. Calc'd for C₁₆H₁₄N₃SO₂Cl: C,52.82; H, 3.88; N, 11.55. Found: C, 52.91; H, 3.88; N, 11.50.

Step 5. Preparation of[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]methyl]-N,O-bis(phenoxycarbonyl)hydroxylamine.

A solution of4-[5-(4-chlorophenyl)-3-hydroxymethyl-1H-pyrazol-1-yl]benzenesulfonamidefrom Step 4 (7.28 g, 0.02 mol), triphenylphosphine (6.29 g, 0.024 mol)and N,O-bis(phenoxycarbonyl)hydroxylamine prepared as-described by A. O.Stewart and D. W. Brooks, [J. Org. Chem., 57, 5020-5023 (1992)] (6.01 g,0.022 mol) in 250 mL of anhydrous tetrahydrofuran (THF) was cooled to 0°C. and treated with diisopropylazo-dicarboxylate (3.75 g, 0.024 mol)dissolved in 25 mL of THF. The solution was stirred at room temperaturefor 3 hours, concentrated in vacuo and the residue purified by flashchromatography on silica gel eluting with ethyl acetate/hexane (2:3) toafford 9.30 g, 75% of the protected hydroxylamine as a thick clear oilthat was used directly in the next step.

Step 6. Preparation of N′-[[1-[4-(aminosulfonyl)Phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea.

The compound from Step 5 (6.0 g, 9.7 mmol) was dissolved in 150 mL ofethanol and the solution was saturated with ammonia. The solution waslet stand undisturbed overnight and then concentrated in vacuo. Theresidue was dissolved in ethyl acetate, washed with 1 N HCl and brine,dried over anhyd. MgSO₄, filtered and concentrated in vacuo to affordN′-[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyureaas a white solid that was crystallized from a mixture of ethyl acetateand hexane: mp 216-218° C.

EXAMPLE 2

A solution of4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-oxazoleproprionic acid(U.S. Pat. No. 5,380,738) (500 mg, 1.28 mmol) was dissolved in 20 mL ofdichloromethane containing 50 μL of dimethylformamide (DMF). Thissolution was cooled to 0° C. and treated with oxalyl chloride (130 μL,1.54 mmol, 1.2 equivalents). The solution was warmed to room temperatureand stirred for 3 hours, and concentrated in vacuo. The residue wastaken back up in dichloromethane and added dropwise to a solution ofN-methyl hydroxylamine hydrochloride (129 mg, 1.54 mmol, 1.2equivalents) and triethylamine (390 μL, 2.82 mmol, 2.2 equivalents) in20 mL of dichloromethane at 0° C. The solution was stirred at roomtemperature for 1 hour and diluted with water. The phases were separatedand the dichloromethane layer was washed with 1 N HCl, brine, dried overanhydrous MgSO₄, filtered and concentrated in vacuo to provide a yellowsolid that was recrystallized from a mixture of ethyl acetate andisooctane to provide4-(4-fluorophenyl)-N-hydroxy-N-methyl-5-[(4-methylsulfonyl)phenyl]-2-oxazolepropanamide (455 mg, 85%): ¹H-NMR (CDCl₃, 300 MHz)-3.12(s, 3H), 3.15 (t, 2H, J=6.6 Hz), 3.28 (s, 3H), 3.41 (t, 2H, J=6.6 Hz),7.20 (t, 2H, J=8.5 Hz), 7.54 (m, 2H), 7.75 (d, 2H, J=8.5 Hz) and 7.97(d, 2H, J=8.5 Hz). LRMS m/z 418 (M)+. HRMS calc'd. for C₂₀H₁₉N₂O₅FS:418.0999. Found: 418.0987. Anal. calc'd. for C₂₀H₁₉N₂O₅FS: C, 57.41; H,4.58; N, 6.69. Found: C, 56.84; H, 4.50; N, 6.59.

EXAMPLE 3

Step 1. Preparation of4-[5-(4-chlorophenyl)-3-chloromethyl-1H-pyrazol-1-yl]benzenesulfonamide.

4-[5-(4-Chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide(Example 1 Step 4) (3.0 g, 8.2 mmol) was dissolved in 100 mL of drytetrahydrofuran and treated with para-toluenesulfonyl chloride (1.56 g,8.2 mmol), lithium chloride (350 mg, 8.2 mmol), and triethylamine (830mg, 8.2 mmol). The solution was warmed to reflux for 16 hours anddiluted with 100 mL of ethyl acetate. The solution was washed with 1 Nhydrochloric acid, saturated aqueous NaHCO₃, and water, dried overanhydrous MgSO₄, filtered and concentrated in vacuo. The residue waspurified by flash chromatography over silica gel eluting with 1:1 (v:v)hexane/ethyl acetate. The appropriate fractions were combined andconcentrated and the residue crystallized from ethanol/water to givepure4-[5-(4-chlorophenyl)-3-chloromethyl-1H-pyrazol-1-yl]benzenesulfonamideas a white solid (2.51 g, 80%): mp 198-201° C. Anal. Calc'd. forC₁₆H₁₃N₃S₁O₂Cl₂: C, 50.27; H, 3.43; N, 10.99. Found: C, 50.34; H, 3.43;N, 10.96.

Step 2. Preparation of4-[5-(4-chlorophenyl)-3-cyanomethyl-1-H-pyrazol-1-yl]benzenesulfonamide.

A solution of4-[5-(4-chlorophenyl)-3-chloromethyl-1H-pyrazol-1-yl]benzenesulfonamidefrom step 1 (350 mg, 0.9 mmol) and sodium cyanide (200 mg), dissolved in15 mL of dimethylsulfoxide, was warmed to 100° C. for 4 hours. Thesolution was cooled to room temperature, diluted with water andextracted with ethyl acetate. The ethyl acetate extracts were combinedand washed with water, dried over anhydrous MgSO₄, filtered andconcentrated in vacuo. The residue was purified by flash chromatographyover silica gel eluting with 1:1 (v:v) hexane/ethyl acetate. Theappropriate fractions were combined and concentrated, and the residuecrystallized from ethanol/water to give4-[5-(4-chlorophenyl)-3-cyanomethyl-1-H-pyrazol-1-yl]benzenesulfonamideas a white solid (251 mg, 75%): mp 212-214° C. Anal. Calc'd. forC₁₇H₁₃ClN₄O₂S₁: C, 54.77; H, 3.51; N, 15.03. Found: C, 54.94; H, 3.61;N, 14.88.

Step 3. Preparation of[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]aceticAcid.

To a solution of4-[5-(4-chlorophenyl)-3-(cyanomethyl)-1H-pyrazol-1-yl]benzenesulfonamidefrom step 2 (0.340 g, 3.594 mmol) in ethanol (250 mL) at −10° C., HClgas was added via a fritted gas inlet tube over 6 hours. The reactionmixture was concentrated in vacuo yielding an oil. The oil was dissolvedin 50 mL of ethanol and 15 mL of water, treated with LiOH until the pHwas 12, and stirred at room temperature overnight. The reaction wasconcentrated in vacuo, diluted with water, acidified with dil HCl, andextracted with ethyl acetate. The ethyl acetate phase was dried overanhydrous MgSO₄, filtered and concentrated yielding[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]aceticacid as a brown solid (1.072 g, 76%): mp 120-122° C. High resolutionmass spectrum Calc'd. for C₁₇H₁₅ClN₃O₄S (M+H): 392.0472. Found:392.0467. ¹H NMR (CDCl₃ and CD₃CO₂D) 7.84 (d, J=8.66 Hz 2H), 7.37 (d,J=8.66 Hz, 2H), 7.31 (d, J=8.66 Hz, 2H), 7.15 (d, J=8.66 Hz, 2H), 6.54(s, 1H), 3.84 (s, 2H)

Step 4. Preparation of[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methylacetamide.

To a stirred solution of the1-(4-aminosulfonylphenyl)-4-(4-chlorophenyl)pyrazole-3-acetic acid fromstep 3 (0.240 g, 0.613 mmol) in dioxane (6 mL) was addedN-hydroxysuccinimide (0.085 g, 0.735 mmol) and1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (0.129g, 0.674 mmol). After stirring overnight, the reaction mixture wasconcentrated in vacuo and diluted with ethyl acetate. The ethyl acetatephase was washed with KHSO₄, NaHCO₃, and brine, dried over MgSO₄,filtered and concentrated in vacuo yielding the crudeN-hydroxysuccinimide ester. This ester and N-methylhydroxylamide HCl(0.056 g, 0.674 mmol) were dissolved in dimethylformamide, (4 mL) andtriethylamine (94 μL, 0.068 g, 0.674 mmol) was added. The reaction wasstirred at room temperature for 56 hours, diluted with ethyl acetate,washed with KHSO₄, dried over anhydrous MgSO₄, filtered and concentratedin vacuo yielding a semi-solid. This solid was treated with isooctaneand ethyl acetate yielding[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]-N-hydroxy-N-methylacetamide as an off-white powder (0.083 g, 32%): mp 110-135° C. (dec).¹H NMR (CDCl₃ and DMSO d₆) 9.45 (s, 1H exch), 7.86 (d, J=8.86 Hz, 2H),7.27-7.40 (m, 4H), 7.12 (d, J=8.46 Hz, 2H), 6.49, S, 1H), 5.98 (s, 2H),3.89 (s, 2H), 3.25 (s, 3H). LRMS: M⁺ obs at 421.

EXAMPLE 4

Step 1. Preparation of2-(3,4-dichlorophenyl)-2-hydroxy-1-phenylethanone.

Trimethylsilyl cyanide (14.6 g, 0.147 mol) was dissolved in 30 mL ofmethylene chloride and added to a solution of 3,4-dichlorobenzaldehyde(25 g, 0.143 mol) and zinc iodide (0.41 g, 1.28 mmol) in 100 mL ofmethylene chloride. The reaction mixture was stirred at room temperaturefor 1 h and diluted with 200 mL of methylene chloride. The organic layerwas washed with saturated sodium bicarbonate (2×150 mL), saturated brine(2×150 mL), dried over magnesium sulfate, filtered and concentrated togive 38.4 g (98%) of a brown oil, which was used in the next reactionwithout further purification. This trimethylsilyl cyanohydrin (15 g,0.0547 mol) was dissolved in 20 mL of diethyl ether and added tophenylmagnesium bromide (19.5 mL of 3.0 M in ether solution, 0.0585 mol)in 250 mL of ether. The reaction mixture was stirred for 1.5 h at roomtemperature, then slowly quenched with 100 mL of 3 N HCl. The organiclayer was separated and washed with saturated sodium bicarbonate (1×150mL), saturated brine (1×150 mL), dried over magnesium sulfate, filteredand concentrated to give 13.0 g of a brown oil. A solution of 9:1trifluoroacetic acid in water (50 mL) was added to the concentratedresidue, and the mixture was stirred for 1.5 h at room temperature. Thereaction mixture was neutralized by adding solid sodium carbonate. Theresulting residue was partitioned between water (200 mL) and ethylacetate (300 mL). The organic layer was separated and washed withsaturated sodium bicarbonate (1×150 mL), saturated brine (1×150 mL),dried over magnesium sulfate, filtered and concentrated. Theconcentrated residue was crystallized from ethyl acetate and hexane togive 7.37 g (48%) of 2-(3,4-dichlorophenyl)-2-hydroxy-1-(phenyl)ethanoneas a yellow solid: HRMS calcd. for C₁₄H₁₀O₂Cl₂ 281.0136, found 281.0112.

Step 2. Preparation of Methyl[(4-phenyl)-5-(3,4-dichlorophenyl)oxazole]-2-butanoate.

5-(Methoxycarbonyl)pentanoyl chloride (2.82 g, 0.017 mol) andtriethylamine (3.47 g, 0.034 mol) were added to a solution of2-(3,4-dichlorophenyl)-2-hydroxy-1-[phenyl]ethanone (Step 1) (4.77 g,0.017 mmol) in 40 mL of methylene chloride. The resulting mixture wasstirred overnight at room temperature. The reaction mixture was dilutedwith 100 mL of methylene chloride. The organic solution was washed withwater (1×100 mL), saturated brine (1×100 mL), dried over magnesiumsulfate, filtered and concentrated. The concentrated residue was driedunder high vacuum, then ammonium acetate (4.6 g, 0.06 mol) and 30 mL ofacetic acid were added. The reaction mixture was heated at 100° C. for2.5 h. The reaction mixture was cooled to room temperature, and theexcess acetic acid was removed under vacuum. The resulting residue waspartitioned between water (100 mL) and ethyl acetate (200 mL). Theorganic layer was separated, washed with saturated aqueous sodiumbicarbonate (2×100 mL), saturated brine (1×100 mL), dried over magnesiumsulfate, filtered and concentrated. The concentrated residue waspurified by flash chromatography on silica gel (eluting with 1:9 ethylacetate:hexane) to give 2.82 g (42.6%) of methyl[(4-phenyl)-5-(3,4-dichlorophenyl)oxazole]-2-butanoate as a yellow oil:HRMS calcd. for C₂₀H₁₇N₁O₃Cl₂ 390.0664. Found 390.0648.

Step 3. Preparation of Methyl4-[(4-aminosulfonyl)phenyl]-5-(3,4-dichloro-phenyl)oxazole-2-butanoate.

Chlorosulfonic acid (28 g, 0.24 mol) was added to methyl[(4-phenyl)-5-(3,4-dichlorophenyl)oxazole]-2-butanoate (Step 2) (3.74 g,9.58 mmol) at 5° C. The ice bath was removed, and the reaction wasstirred for 3 h at room temperature. The reaction mixture was dilutedwith 100 mL of methylene chloride and slowly poured into ice. Theorganic layer was separated and washed with saturated brine (1×100 mL).The organic layer was separated and poured into 50 mL of concentratedammonium hydroxide. The reaction mixture was stirred for 30 minutes atroom temperature. The organic layer was separated and washed with water(1×100 mL), saturated brine (1×100 mL), dried over magnesium sulfate,filtered and concentrated. The crude ester was crystallized frommethanol and water to give 1.7 g (38%) of methyl4-[(4-aminosulfonyl)phenyl]-5-(3,4-dichloro-phenyl)oxazole-2-butanoateas a yellow solid: m.p. 130.7-131.8° C. HRMS calcd. for C₂₀H₁₈N₂O₅SCl₂469.0392. Found 469.0413.

Step 4. Preparation of4-[(4-aminosulfonyl)thenyl]-5-(3,4-dichlorophenyl)-N-hydroxy-2-oxazolebutanamide.

An aqueous solution of 50% N-hydroxylamine (1 g) was added to methyl4-[(4-aminosulfonyl)phenyl]-5-(3,4-dichlorophenyl)oxazole-2-butanoate(Step 3) (0.3 g, 0.64 mmol) in 10 mL of THF:methanol (1:1). Theresulting solution was stirred for 18 h at room temperature. Anadditional amount of aqueous 50% N-hydroxylamine (2.7 g) was added, andthe resulting solution was stirred for 48 h at room temperature. Thesolvents were removed under vacuum. Water (50 mL) and ethyl acetate (50mL) were added to the concentrated residue. The resulting solid wascollected by filtration, washed with water and ether, and air-dried togive 0.14 g (46.5%) of4-[(4-aminosulfonyl)phenyl]-5-(3,4-dichlorophenyl)-N-hydroxy-2-oxazolebutanamideas a white solid: m.p. 165.0-169.7° C. ¹H NMR (CD₃OD/300 MHz) δ2.15-2.27(m, 4H), 2.94

(t, 2H, J=7.05 Hz),

7.44−7.48(m, 1H), 7.56−7.58(m, 1H), 7.72−7.78

(m, 3H), 7.94-7.96 (m, 2H). HRMS: calcd for C₁₉H₁₇N₃O₅SCl₂ 470.0344.Found 470.0340.

Biological Evaluation

Rat Carrageenan Foot Pad Edema Test

The carrageenan foot edema test was performed with materials, reagentsand procedures essentially as described by Winter, et al., (Proc. Soc.Exp. Biol. Med., 111, 544 (1962)). Male Sprague-Dawley rats wereselected in each group so that the average body weight was as close aspossible. Rats were fasted with free access to water for over sixteenhours prior to the test. The rats were dosed orally (1 mL) withcompounds suspended in vehicle containing 0.5% methylcellulose and0.025% surfactant, or with vehicle alone. One hour later a subplantarinjection of 0.1 mL of 1% solution of carrageenan/sterile 0.9% salinewas administered and the volume of the injected foot was measured with adisplacement plethysmometer connected to a pressure transducer with adigital indicator. Three hours after the injection of the carrageenan,the volume of the foot was again measured. The average foot swelling ina group of drug-treated animals was compared with that of a group ofplacebo-treated animals and the percentage inhibition of edema wasdetermined (Otterness and Bliven, Laboratory Models for Testing NSAIDS,in Non-steroidal Anti-Inflammatorv Drugs, (J. Lombardino, ed. 1985)).The % inhibition shows the % decrease from control paw volume determinedin this procedure and the data for selected compounds in this inventionare summarized in Table I.

TABLE I RAT PAW EDEMA % Inhibition @ 10 mg/kg body weight Example 2 2

Evaluation of COX-1 and COX-2 activity in vitro

The compounds of this invention exhibited inhibition in vitro of COX-2.The COX-2 inhibition activity of the compounds of this inventionillustrated in the Examples was determined by the following methods.

a. Preparation of Recombinant Cox Baculoviruses

Recombinant COX-1 and COX-2 were prepared as described by Gierse et al,[J. Biochem., 305, 479-84 (1995)]. A 2.0 kb fragment containing thecoding region of either human or murine COX-1 or human or murine COX-2was cloned into a BamH1 site of the baculovirus transfer vector pVL1393(Invitrogen) to generate the baculovirus transfer vectors for COX-1 andCOX-2 in a manner similar to the method of D. R. O'Reilly et al(Baculovirus Expression Vectors: A Laboratory Manual (1992)).Recombinant baculoviruses were isolated by transfecting 4 μg ofbaculovirus transfer vector DNA into SF9 insect cells (2×10⁸) along with200 ng of linearized baculovirus plasmid DNA by the calcium phosphatemethod. See M. D. Summers and G. E. Smith, A Manual of Methods forBaculovirus Vectors and Insect Cell Culture Procedures, Texas Agric.Exp. Station Bull. 1555 (1987). Recombinant viruses were purified bythree rounds of plaque purification and high titer (10⁷⁻¹⁰ ⁸ pfu/ml)stocks of virus were prepared. For large scale production, SF9 insectcells were infected in 10 liter fermentors (0.5×10⁶/ml) with therecombinant baculovirus stock such that the multiplicity of infectionwas 0.1. After 72 hours the cells were centrifuged and the cell pellethomogenized in Tris/Sucrose (50 mM: 25%, pH 8.0) containing 1%3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS). Thehomogenate was centrifuged at 10,000×G for 30 minutes, and the resultantsupernatant was stored at −80° C. before being assayed for COX activity.

b. Assay for COX-1 and COX-2 Activity

COX activity was assayed as PGE₂ formed/g protein/time using an ELISA todetect the prostaglandin released. CHAPS-solubilized insect cellmembranes containing the appropriate COX enzyme were incubated in apotassium phosphate buffer (50 mM, pH 8.0) containing epinephrine,phenol, and heme with the addition of arachidonic acid (10 μM).Compounds were pre-incubated with the enzyme for 10-20 minutes prior tothe addition of arachidonic acid. Any reaction between the arachidonicacid and the enzyme was stopped after ten minutes at 37° C./roomtemperature by transferring 40 μl of reaction mix into 160 μl ELISAbuffer and 25 μM indomethacin. The PGE₂ formed was measured by standardELISA technology (Cayman Chemical). Results are shown in Table II.

Assay for 5-Lipoxygenase Activity

The 5-lipoxygenase (5-LO) activity of the compounds were determined bythe calcium ionophore-induced Leukotriene B4 (LTB4) production in humanwhole blood. Venous blood was collected from healthy human donors usingheparin as an anti-coagulant. Human blood samples (0.2 ml of a 1:4dilution in RPMI 1640 medium) were incubated in 96-well culture platesfor 15 minutes at 37° C. with test compounds dissolved in ethanol (EtOH;final concentration <1%), or vehicle. Typically 7 concentrations of testcompounds were examined in duplicate. A-23187 [Sigma] was added to theblood to a final concentration of 20 μg/ml, and the mixtures wereincubated for 10 minutes at 37° C. The reaction was stopped by placingthe samples on ice. The samples were then centrifuged at 800×g at 4° C.for 10 minutes to pellet the cells, and the supernatants were recoveredfor quantitation of LTB4 by ELISA (Cayman Chemical Co.; sensitivity 3pg/ml). IC₅₀'s were estimated from a four parameter logistic model withtwo parameters fixed, the minimum (0% inhibition) and maximum (100%inhibition). The IC₅₀ value is the concentration that produces 50%inhibition between the fixed values of the minimum and maximum. Data isreported as the mean IC₅₀ for each compound. Results are shown in TableII.

TABLE II COX-2 COX-1 5-LO Example IC₅₀ (μM) IC₅₀ (μM) IC₅₀ (μM) 1 6.653.5 12.3 2 5.1 >100 0.05 4 0.3 12.5

Also embraced within this invention is a class of pharmaceuticalcompositions comprising the active compounds of this combination therapyin association with one or more non-toxic, pharmaceutically-acceptablecarriers and/or diluents and/or adjuvants (collectively referred toherein as “carrier” materials) and, if desired, other activeingredients. The active compounds of the present invention may beadministered by any suitable route, preferably in the form of apharmaceutical composition adapted to such a route, and in a doseeffective for the treatment intended. The active compounds andcomposition may, for example, be administered orally, intravascularly(IV), intraperitoneally, subcutaneously, intramuscularly (IM) ortopically.

For oral administration, the pharmaceutical composition may be in theform of, for example, a tablet, hard or soft capsule, lozenges,dispensable powders, suspension or liquid. The pharmaceuticalcomposition is preferably made in the form of a dosage unit containing aparticular amount of the active ingredient. Examples of such dosageunits are tablets or capsules.

The active ingredient may also be administered by injection (IV, IM,subcutaneous or jet) as a composition wherein, for example, saline,dextrose, or water may be used as a suitable carrier. The pH of thecomposition may be adjusted, if necessary, with suitable acid, base, orbuffer. Suitable bulking, dispersing, wetting or suspending agents,including mannitol and PEG 400, may also be included in the composition.A suitable parenteral composition can also include a compound formulatedas a sterile solid substance, including lyophilized powder, in injectionvials. Aqueous solution can be added to dissolve the compound prior toinjection.

The amount of therapeutically active compounds that are administered andthe dosage regimen for treating a disease condition with the compoundsand/or compositions of this invention depends on a variety of factors,including the age, weight, sex and medical condition of the subject, theseverity of the inflammation or inflammation related disorder, the routeand frequency of administration, and the particular compound employed,and thus may vary widely. The prodrug compositions should includesimilar dosages as for the parent compounds. The pharmaceuticalcompositions may contain active ingredients in the range of about 0.1 to1000 mg, preferably in the range of about 0.5 to 250 mg and mostpreferably between about 1 and 60 mg. A daily dose of about 0.01 to 100mg/kg body weight, preferably between about 0.05 and about 20 mg/kg bodyweight and most preferably between about 0.1 to 10 mg/kg body weight,may be appropriate. The daily dose can be administered in one to fourdoses per day.

In the case of skin conditions, it may be preferable to apply a topicalpreparation of compounds of this invention to the affected area two tofour times a day.

For disorders of the eye or other external tissues, e.g., mouth andskin, the formulations are preferably applied as a topical gel, spray,ointment or cream, or as a suppository, containing the activeingredients in a total amount of, for example, 0.075 to 30% w/w,preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. Whenformulated in an ointment, the active ingredients may be employed witheither paraffinic or a water-miscible ointment base. Alternatively, theactive ingredients may be formulated in a cream with an oil-in-watercream base. If desired, the aqueous phase of the cream base may include,for example at least 30% w/w of a polyhydric alcohol such as propyleneglycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethyleneglycol and mixtures thereof. The topical formulation may desirablyinclude a compound which enhances absorption or penetration of theactive ingredient through the skin or other affected areas. Examples ofsuch dermal penetration enhancers include dimethylsulfoxide and relatedanalogs. The compounds of this invention can also be administered by atransdermal device. Preferably topical administration will beaccomplished using a patch either of the reservoir and porous membranetype or of a solid matrix variety. In either case, the active agent isdelivered continuously from the reservoir or microcapsules through amembrane into the active agent permeable adhesive, which is in contactwith the skin or mucosa of the recipient. If the active agent isabsorbed through the skin, a controlled and predetermined flow of theactive agent is administered to the recipient. In the case ofmicrocapsules, the encapsulating agent may also function as themembrane. The transdermal patch may include the compound in a suitablesolvent system with an adhesive system, such as an acrylic emulsion, anda polyester patch.

The oily phase of the emulsions of this invention may be constitutedfrom known ingredients in a known manner. While the phase may comprisemerely an emulsifier, it may comprise a mixture of at least oneemulsifier with a fat or an oil or with both a fat and an oil.Preferably, a hydrophilic emulsifier is included together with alipophilic emulsifier which acts as a stabilizer. It is also preferredto include both an oil and a fat. Together, the emulsifier(s) with orwithout stabilizer(s) make-up the so-called emulsifying wax, and the waxtogether with the oil and fat make up the so-called emulsifying ointmentbase which forms the oily dispersed phase of the cream formulations.Emulsifiers and emulsion stabilizers suitable for use in the formulationof the present invention include Tween 60, Span 80, cetostearyl alcohol,myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate,among others.

The choice of suitable oils or fats for the formulation is based onachieving the desired cosmetic properties, since the solubility of theactive compound in most oils likely to be used in pharmaceuticalemulsion formulations is very low. Thus, the cream should preferably bea non-greasy, non-staining and washable product with suitableconsistency to avoid leakage from tubes or other containers. Straight orbranched chain, mono- or dibasic alkyl esters such as di-isoadipate,isocetyl stearate, propylene glycol diester of coconut fatty acids,isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate,2-ethylhexyl palmitate or a blend of branched chain esters may be used.These may be used alone or in combination depending on the propertiesrequired. Alternatively, high melting point lipids such as white softparaffin and/or liquid paraffin or other mineral oils can be used.

Formulations suitable for topical administration to the eye also includeeye drops wherein the active ingredients are dissolved or suspended insuitable carrier, especially an aqueous solvent for the activeingredients. The antiinflammatory active ingredients are preferablypresent in such formulations in a concentration of 0.5 to 20%,advantageously 0.5 to 10% and particularly about 1.5% w/w.

For therapeutic purposes, the active compounds of this combinationinvention are ordinarily combined with one or more adjuvants appropriateto the indicated route of administration. If administered per os, thecompounds may be admixed with lactose, sucrose, starch powder, celluloseesters of alkanoic acids, cellulose alkyl esters, talc, stearic acid,magnesium stearate, magnesium oxide, sodium and calcium salts ofphosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate,polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted orencapsulated for convenient administration. Such capsules or tablets maycontain a controlled-release formulation as may be provided in adispersion of active compound in hydroxy-propylmethyl cellulose.Formulations for parenteral administration may be in the form of aqueousor non-aqueous isotonic sterile injection solutions or suspensions.These solutions and suspensions may be prepared from sterile powders orgranules having one or more of the carriers or diluents mentioned foruse in the formulations for oral administration. The compounds may bedissolved in water, polyethylene glycol, propylene glycol, ethanol, cornoil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodiumchloride, and/or various buffers. Other adjuvants and modes ofadministration are well and widely known in the pharmaceutical art.

Although this invention has been described with respect to specificembodiments, the details of these embodiments are not to be construed aslimitations.

What is claimed is:
 1. A compound of Formula III

wherein A is pyrazolyl optionally substituted with a substituentselected from acyl, halo, hydroxyl, lower alkyl, lower haloalkyl, oxo,cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, loweralkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lowerhydroxyalkyl; wherein Y is selected from lower alkylene, loweralkenylene and lower alkynylene; wherein R¹ is a substituent selectedfrom 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyland aryl selected from phenyl, biphenyl and naphthyl, wherein R¹ isoptionally substituted at a substitutable position with one or moresubstituents selected from lower alkyl, lower haloalkyl, cyano,carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lowerhaloalkoxy, amino, lower alkylamino, phenylmino, nitro, loweralkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and loweralkylthio; wherein R² is selected from lower alkyl and amino; andwherein R⁵ is selected from hydrido, lower alkyl; or apharmaceutically-acceptable salt thereof.
 2. Compound of claim 1 whereinA is optionally substituted with a substituent selected from formyl,fluoro, chloro, bromo, methyl, trifluoromethyl, oxo, cyano, carboxyl,methoxy, aminocarbonyl, methoxycarbonyl, ethoxycarbonyl, acetyl,carboxypropyl, and hydroxymethyl; wherein Y is selected from methylene,ethylene, isopropylene, propylene, butylene, propenylene, butenylene,propynylene and butynylene; wherein R¹ is selected from thienyl,oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl,pyridyl, and phenyl, where R¹ is optionally substituted at asubstitutable position with one or more substituents selected frommethyl, trifluoromethyl, hydroxyl, hydroxymethyl, trifluoromethoxy,methoxymethyl, fluoro, chloro, bromo, methoxy and methylthio; wherein R²is methyl or amino; and wherein R⁵ is selected from hydrido, methyl, andphenyl; or a pharmaceutically-acceptable salt thereof.
 3. A compoundaccording to claim 1 which isN′-[[1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazol-3-yl]methyl]-N′-hydroxyurea.4. A compound of Formula II

wherein A is pyrazolyl optionally substituted with a substituentselected from acyl, halo, hydroxyl, lower alkyl, lower haloalkyl, oxo,cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, loweralkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lowerhydroxyalkyl; wherein Y is selected from lower alkenylene and loweralkynylene; wherein R¹ is a substituent selected from 5- and 6-memberedheterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected fromphenyl, biphenyl and naphthyl, wherein R¹ is optionally substituted at asubstitutable position with one or more substituents selected from loweralkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl,lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino,phenylmino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, loweralkoxy and lower alkylthio; wherein R² is selected from lower alkyl andamino; and wherein R⁵ is selected from hydrido, lower alkyl, phenyl, 5-and 6-membered heterocyclo and lower cycloalkyl; or apharmaceutically-acceptable salt thereof.
 5. Compound of claim 4 whereinA is pyrazolyl optionally substituted with a substituent selected fromformyl, fluoro, chloro, bromo, methyl, trifluoromethyl, oxo, cyano,carboxyl, methoxy, aminocarbonyl, methoxycarbonyl, ethoxycarbonyl,acetyl, carboxypropyl, and hydroxymethyl; wherein Y is selected frompropenylene, butenylene, propynylene and butynylene; wherein R¹ isselected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl,isoxazolyl, pyrazolyl, pyridyl, and phenyl, where R¹ is optionallysubstituted at a substitutable position with one or more substituentsselected from methyl, trifluoromethyl, hydroxyl, hydroxymethyl,trifluoromethoxy, methoxymethyl, fluoro, chloro, bromo, methoxy andmethylthio; wherein R² is methyl or amino; and wherein R⁵ is selectedfrom hydrido, methyl, and phenyl; or a pharmaceutically-acceptable saltthereof.
 6. A pharmaceutical composition comprising atherapeutically-effective amount of a compound of claim 4, or apharmaceutically-acceptable salt thereof.
 7. A method for treating acyclooxygenase-2, a 5-lipoxygenase, or a 5-lipoxygenase andcyclooxygenase-2 disorder in a mammal in need of such treatment,comprising treating the mammal with a therapeutically-effective amountof a compound of claim 4, or a pharmaceutically-acceptable salt thereof.8. The method according to claim 7 wherein the condition is inflammationor an inflammation-associated disorder.
 9. The method according to claim8 wherein the condition is inflammation.
 10. The method of claim 8wherein the condition is an inflammation-associated disorder.
 11. Themethod of claim 10 wherein the inflammation-associated disorder isarthritis.
 12. The method of claim 10 wherein theinflammation-associated disorder is pain.
 13. The method of claim 10wherein the inflammation-associated disorder is fever.